<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vilanterol and fluticasone furoate for asthma - Dwan, K - 2016 | Cochrane Library</title> <meta content="Vilanterol and fluticasone furoate for asthma - Dwan, K - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010758.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vilanterol and fluticasone furoate for asthma - Dwan, K - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010758.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010758.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Vilanterol and fluticasone furoate for asthma" name="citation_title"/> <meta content="Kerry Dwan" name="citation_author"/> <meta content="Cochrane Central Executive" name="citation_author_institution"/> <meta content="Stephen J Milan" name="citation_author"/> <meta content="Lancaster University" name="citation_author_institution"/> <meta content="Lynne Bax" name="citation_author"/> <meta content="Lancashire Care NHS Foundation Trust" name="citation_author_institution"/> <meta content="Nicola Walters" name="citation_author"/> <meta content="St George's University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Colin VE Powell" name="citation_author"/> <meta content="Cardiff University" name="citation_author_institution"/> <meta content="PowellC7@cardiff.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD010758.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/09/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010758.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010758.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010758.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010758.pub2&amp;doi=10.1002/14651858.CD010758.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010758\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010758\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","hr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010758.pub2",title:"Vilanterol and fluticasone furoate for asthma",firstPublishedDate:"Sep 1, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010758.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010758.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010758.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010758.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010758.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010758.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010758.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010758.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010758.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010758.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2680 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010758.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-sec-0126"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/appendices#CD010758-sec-0137"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/table_n/CD010758StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/table_n/CD010758StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vilanterol and fluticasone furoate for asthma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information#CD010758-cr-0002">Kerry Dwan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information#CD010758-cr-0003">Stephen J Milan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information#CD010758-cr-0004">Lynne Bax</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information#CD010758-cr-0005">Nicola Walters</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information#CD010758-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Colin VE Powell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information/en#CD010758-sec-0147">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 September 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010758.pub2">https://doi.org/10.1002/14651858.CD010758.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010758-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010758-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010758-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010758-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010758-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010758-abs-0001" lang="en"> <section id="CD010758-sec-0001"> <h3 class="title" id="CD010758-sec-0001">Background</h3> <p>Vilanterol (VI) is a long‐acting beta<sub>2</sub>‐agonist (LABA) that binds to the beta<sub>2</sub>‐adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Society (BTS) Guidelines for the Management of Asthma, leads to improvement in symptoms and lung function and reduction in exacerbations. At present, the commonly used LABAs licensed for use in asthma management (formoterol and salmeterol) require twice‐daily administration, whereas VI is a once‐daily therapy. </p> <p>Fluticasone furoate (FF) is an inhaled corticosteroid (ICS), and ICS therapy is recommended by the BTS asthma guidelines. ICSs, the mainstay of asthma treatment, lead to a reduction in both airway inflammation and airway hyper‐responsiveness. Regular use leads to improvement in symptoms and lung function. ICSs are currently recommended as 'preventer' therapy for patients who use a 'reliever' medication (e.g. short‐acting beta<sub>2</sub> agonist (SABA), salbutamol) three or more times per week. Most of the commonly used ICS treatments are twice‐daily medications, although two once‐daily products are currently licensed (ciclesonide and mometasone). </p> <p>At the present time, only one once‐daily ICS/LABA combination (FF/VI) is available, and several other combination inhalers are recommended for twice‐daily administration. </p> </section> <section id="CD010758-sec-0002"> <h3 class="title" id="CD010758-sec-0002">Objectives</h3> <p>To compare effects of VI and FF in combination versus placebo, or versus other ICSs and/or LABAs, on acute exacerbations and on health‐related quality of life (HRQoL) in adults and children with chronic asthma. </p> </section> <section id="CD010758-sec-0003"> <h3 class="title" id="CD010758-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Register of trials, clinical trial registries, manufacturers' websites and reference lists of included studies up to June 2016. </p> </section> <section id="CD010758-sec-0004"> <h3 class="title" id="CD010758-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of adults and children with a diagnosis of asthma. Included studies compared VI and FF combined versus placebo, or versus other ICSs and/or LABAs. Our primary outcomes were health‐related quality of life, severe asthma exacerbation, as defined by hospital admissions or treatment with a course of oral corticosteroids, and serious adverse events. </p> </section> <section id="CD010758-sec-0005"> <h3 class="title" id="CD010758-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and analysed outcomes using a fixed‐effect model. We used standard Cochrane methods. </p> </section> <section id="CD010758-sec-0006"> <h3 class="title" id="CD010758-sec-0006">Main results</h3> <p>We identified 14 studies that met our inclusion criteria, with a total of 6641 randomised participants, of whom 5638 completed the study. All studies lasted between two and 78 weeks and showed good methodological quality overall. </p> <p>We included 10 comparisons in this review, seven for which the dose of VI and FF was 100/25 mcg (VI/FF 100/25 mcg vs placebo; VI/FF 100/25 mcg vs same dose of FF; VI/FF 100/25 mcg vs same dose of VI; VI/FF 100/25 mcg vs fluticasone propionate (FP) 500 mcg twice‐daily; VI/FF 100/25 mcg vs fluticasone propionate/salmeterol (FP/SAL) 250/50 mcg twice‐daily; VI/FF 100/25 mcg vs FP/SAL 250/25 mcg twice‐daily; FF/VI 100/25 vs FP/SAL500/50) and three for which the dose of VI and FF was 200/25 mcg (VI/FF 200/25 mcg vs placebo; VI/FF 200/25 mcg vs FP 500 mcg; VI/FF 200/25 mcg vs same dose of FF). </p> <p>We found very few opportunities to combine results from the 14 included studies in meta‐analyses. We tabulated the data for our pre‐specified primary outcomes. In particular, we found insufficient information to assess whether once‐daily VI/FF was better or worse than twice‐daily FP/SAL in terms of efficacy or safety. </p> <p>Only one of the 14 studies looked at health‐related quality of life when comparing VI and FF 100/25 mcg versus placebo and identified a significant advantage of VI/FF 100/25 mcg (mean difference (MD) 0.30, 95% confidence interval (CI) 0.14 to 0.46; 329 participants); we recognised this as moderate‐quality evidence. Only two studies compared VI/FF 100/25 mcg versus placebo with respect to exacerbations; both studies reported no exacerbations in either treatment arm. Five studies (VI/FF 100/25 mcg vs placebo) sought information on serious adverse events; all five studies reported no serious adverse events in the VI/FF 100/25 mcg or placebo arms. We found no comparison relevant to our primary outcomes for VI/FF at a higher dose (200/25 mcg) versus placebo. </p> <p>The small number of studies contributing to each comparison precludes the opportunity to draw robust conclusions for clinical practice. These studies were not of sufficient duration to allow conclusions about long‐term side effects. </p> </section> <section id="CD010758-sec-0007"> <h3 class="title" id="CD010758-sec-0007">Authors' conclusions</h3> <p>Some evidence suggests clear advantages for VI/FF, in combination, compared with placebo, particularly for forced expiratory volume in one second (FEV<sub>1</sub>) and peak expiratory flow; however, the variety of questions addressed in the included studies did not allow review authors to draw firm conclusions. Information was insufficient for assessment of whether once‐daily VI/FF was better or worse than twice‐daily FP/SAL in terms of efficacy or safety. It is clear that more research is required to reduce the uncertainties that surround interpretation of these studies. It will be necessary for these findings to be replicated in other work before more robust conclusions are revealed. Only five of the 13 included studies provided data on health‐related quality of life, and only six recorded asthma exacerbations. Only one study focused on paediatric patients, so no conclusions can be drawn for the paediatric population. More research is needed, particularly in the primary outcome areas selected for this review, so that we can draw firmer conclusions in the next update of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010758-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010758-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010758-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010758-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010758-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010758-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010758-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010758-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010758-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010758-abs-0004" lang="en"> <h3>Vilanterol and fluticasone furoate for chronic asthma in adults and children</h3> <p><b>Review question</b> </p> <p>We considered in this review whether the combination of vilanterol (VI) and fluticasone furoate (FF) is better than placebo for people with asthma. We also compared VI and FF with other inhaled steroids and long‐acting beta<sub>2</sub>‐agonist medications. </p> <p><b>Background</b> </p> <p>Asthma is an inflammatory lung condition whereby the pathway through the airways may become very restricted. By the year 2025, it is estimated that 400 million people will have this condition. Asthma can very seriously affect people's quality of life, and the combination of VI and FF may help to reduce difficulties related to the impact on everyday life of breathlessness and other associated symptoms. </p> <p><b>Study characteristics</b> </p> <p>We included 14 studies in this review, involving a total of 6641 participants. All studies lasted between two and 78 weeks. All people included in these studies had received a diagnosis of asthma. Trials included both men and women, and one study included children and young people. </p> <p>All studies looked at VI and FF versus another medication or placebo. In all studies, the VI/FF combination was taken through a dry powder inhaler. </p> <p><b>Key results</b> </p> <p>We found that participants who received a combination of FF and VI therapy had improved lung function compared with those given placebo, but evidence was insufficient to permit any other conclusions because researchers attempted to answer too many different questions. Evidence was lacking on whether the combination of VI and FF therapy once‐daily is better or worse than a twice‐daily alternative. More studies are needed, so that we can gain a better understanding of the evidence overall. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the evidence presented in this review is taken from well‐designed studies at low risk of bias in terms of decisions on who received which treatment, blinding and how to report outcomes for participants who did not finish the study. However, because we were not able to combine results for many of our outcomes of interest, or because the outcome was rare, we judged the quality of the evidence overall to be low to moderate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010758-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010758-sec-0132"></div> <h3 class="title" id="CD010758-sec-0133">Implications for practice</h3> <section id="CD010758-sec-0133"> <p>Current evidence from 14 studies involving 6641 participants included in this review suggests that the combination of FF and VI may provide safe and effective therapy in the short term compared with placebo. Evidence suggests some improvement in health‐related quality of life, FEV<sub>1</sub> and peak expiratory flow rate (PEFR). However, the limited number of studies combined with the variety of endpoints and the short duration of most trials indicates that firm conclusions cannot be drawn. In particular, information was insufficient for assessment of whether once‐daily VI/FF was better or worse than twice‐daily FP/SAL in terms of efficacy or safety. Additional studies, which would allow meta‐analyses to be undertaken, are required before robust conclusions can be drawn. </p> <p>Very limited evidence is available for its use in paediatric patients, so additional studies in this area are required before conclusions can be drawn for this population. </p> </section> <h3 class="title" id="CD010758-sec-0134">Implications for research</h3> <section id="CD010758-sec-0134"> <p>The 14 studies included in this review are of high quality. However, the diverse nature of the questions addressed in these studies presents a considerable challenge in summarising an overview of the data. It is clear that more research is required to reduce uncertainties arising in the interpretation of currently available evidence. These findings may need to be replicated before robust conclusions can be drawn. Given the short duration of many studies, investigators have not addressed the adrenal axis and cortisol suppression, and we could not comment on concerns around increased asthma deaths associated with other LABAs. These may be important areas for further study. Only five studies provided data on health‐related quality of life, and only six recorded asthma exacerbations. Only one study enrolled paediatric participants, so presently we can draw no conclusions for the paediatric population. Additional data, particularly related to the primary outcomes of this review, derived from longer‐term trials comparing current standard combination therapy would be especially helpful. Data on comparison of VI/FF versus twice‐daily LABA/ICS are sparse, and this topic should be the focus of future research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010758-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010758-sec-0022"></div> <div class="table" id="CD010758-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vilanterol and fluticasone furoate compared with placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>VI and FF compared with placebo for asthma</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with asthma </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> VI and FF </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>VI and FF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.61<br/> (SE 0.061),<br/> n = 149 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.91 (SE 0.055),</p> <p>n = 180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 0.30, 95% CI 0.14 to 0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> (N = 609 participants, 515 completed study) compared VI/FF 100/25 mcg vs placebo in respect of health‐related quality of life and indicated a significant advantage for VI/FF 100/25 mcg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthma exacerbation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 studies (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> and <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>a) compared VI/FF 100/25 mcg vs placebo in respect of exacerbations; both studies reported no exacerbations in either treatment arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Five trials (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0022" title='KempsfordR , AllenA , KellyK , SagguP , CrimC . A repeat dose, double‐blind, placebo‐controlled "Thorough QT/QTc Study" to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered in combination [Abstract]. American Thoracic Society International Conference; 2012 May 18‐23; San Francisco. 2012; Vol. 185, issue Meeting Abstracts:A2841. '>Kempsford 2012a</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) made this same comparison in relation to serious adverse events; all 5 reported no serious adverse events in VI/FF100/25 mcg or placebo arms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.196 L<br/> (SE 0.0310), </p> <p>n = 193</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.368 L</p> <p>(SE 0.0304),</p> <p>n = 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 0.17 L, 95% CI 0.09 to 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant difference in favour of VI/FF 100/25 mcg vs placebo with respect to mean change in trough FEV<sub>1</sub> (pre‐bronchodilator and pre‐dose) from baseline to week 12 in 1 trial (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>) (N = 609 participants, 515 completed study) (MD 0.17 L, 95% CI 0.09 to 0.26), and a similar effect was found in a small cross‐over trial (<a href="./references#CD010758-bbs2-0022" title='KempsfordR , AllenA , KellyK , SagguP , CrimC . A repeat dose, double‐blind, placebo‐controlled "Thorough QT/QTc Study" to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered in combination [Abstract]. American Thoracic Society International Conference; 2012 May 18‐23; San Francisco. 2012; Vol. 185, issue Meeting Abstracts:A2841. '>Kempsford 2012a</a>) over a 2‐week period in the morning (MD 0.377 L, 90% CI 0.293 to 0.462) and in the evening (MD 0.422 L, 90% CI 0.337 to 0.507) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peak expiratory flow</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐0.4 L/min (SE 2.42),<br/> n = 203 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32.9 L/min</p> <p>(SE 2.42),</p> <p>n = 201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 33.30 L/min,</p> <p>95% CI 26.59 to 40.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> (N = 609 participants, 515 completed study) compared VI/FF 100/25 mcg vs placebo as mean change from baseline in daily morning (AM) PEF averaged over 12‐week treatment period; researchers noted a significant difference in favour of VI/FF 100/25 mcg (MD 33.30 L/min, 95% CI 26.59 to 40.01). The same trial showed a similar advantage in favour of VI/FF 100/25 mcg vs placebo in the evening over this period (28.20 L/min, 95% CI 21.67 to 34.73). A small cross‐over trial (<a href="./references#CD010758-bbs2-0022" title='KempsfordR , AllenA , KellyK , SagguP , CrimC . A repeat dose, double‐blind, placebo‐controlled "Thorough QT/QTc Study" to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered in combination [Abstract]. American Thoracic Society International Conference; 2012 May 18‐23; San Francisco. 2012; Vol. 185, issue Meeting Abstracts:A2841. '>Kempsford 2012a</a>) produced a similar effect in favour of VI/FF 100/25 mcg vs placebo over a 2‐week period in the morning (MD 44.0 L/min, 90% CI 31.2 to 56.9) and in the evening (MD 69.0 L/min, 90% CI 55.9 to 82.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthma symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14.6</p> <p>(SE 2.15),</p> <p>n = 202</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32.5 (SE 2.14),</p> <p>n = 201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 17.90, 95% CI 11.95 to 23.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 trial (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>) (N = 609 participants, 515 completed study) made VI/FF vs placebo comparison with respect to asthma symptoms, indicating a clear advantage for VI/FF 100/25 mcg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Several trials reported a range of adverse events for which overall aggregation was not possible. These are tabulated in <a href="./full#CD010758-tbl-0002">Table 8</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> AM: morning; CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in one second; FF: fluticasone furoate; GRADE: Grades of Recommendation, Assessment, Development and Evaluation Working Group; MD: mean difference; OR: odds ratio; PEF: peak expiratory flow; PM: afternoon; RR: risk ratio; SE: standard error; VI: vilanterol </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Point deducted to reflect that these data were derived from only one trial </p> <p><sup>b</sup>Investigators reported no events in either arm of these trials </p> <p><sup>c</sup>Point deducted to reflect that data contributing to the main result (MD 0.17 L, 95% CI 0.09 to 0.26) were obtained from only one trial </p> <p><sup>d</sup>Point deducted, as we were unable to combine data on this outcome; results are presented in a separate table </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010758-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">8.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>200/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VI 25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL</b> </p> <p><b>250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prednisolone </b> </p> <p><b>10 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> </p> <p>6 weeks' duration. On‐treatment AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23/56 (41.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21/56 (38.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5/15 (33.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16/58 (28.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥24 to 78 weeks' duration. On‐treatment AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>636/1009 (63.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>652/1010 (65.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54/346 (15.61%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>67/347 (19.31%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>52/346 (15.03%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29/201 (14.43%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20/205 (9.76%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22/203 (10.84%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> <p>52 weeks' duration. On‐treatment AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>139/201 (69.15%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>134/202 (66.34%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73/100 (73.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>Cross‐over trial. 3 of 7 treatments (2 weeks) separated by 12 to 14‐day washout periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43/172 (25%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25/187 (13%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration. Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>40/155 (26.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41/154 (27.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period between periods </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11/24 (45.83%) AM</b> </p> <p><b>12/25 (48.00%) PM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8/23 (34.78%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66/194 (34.02%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62/197 (31.47%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73/195 (37.44%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a> </p> <p>Cross‐over trial. 11 weeks (for a single period)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4/25 (16.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/25 (4.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a> </p> <p>Cross‐over trial. 28 days for each period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11/51 (21.57%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18/51 (35.29%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15/51 (29.41%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> <p>Cross‐over trial. 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20/27 (74.07%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19/27 (70.37%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22/26 (84.62%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19/27 (70.37%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>110/403 (27.30%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106/403 (26.30%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Fractions shown in the table indicate the proportions of people who suffered one or more adverse events of any cause in each treatment arm </p> <p>AE: adverse event; F: fluticasone furoate; FP: fluticasone propionate; SAL: salmeterol; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010758-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010758-sec-0023"></div> <section id="CD010758-sec-0024"> <h3 class="title" id="CD010758-sec-0024">Description of the condition</h3> <p>Asthma, a chronic respiratory disease, may be well controlled at times, but periods of marked deterioration in symptoms and lung function (referred to as an exacerbation) may abruptly occur. Currently, the number of people with asthma is estimated at 300 million, and forecasts suggest that by 2025, the total will be closer to 400 million (<a href="./references#CD010758-bbs2-0084" title="BousquetJ , KhaltaevN (editors) . Vital signs. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. WHO Press Geneva Centers for Disease Control and Prevention. www.cdc.gov/vitalsigns/asthma/(accessed September 2013). ">WHO 2007</a>). Between 2001 and 2009, the number of people with asthma increased from 20 million to 25 million in the United States, where prevalence rates are slightly lower among adults (8%) than children (10%) (<a href="./references#CD010758-bbs2-0059" title="Centers for Disease Control and Prevention. CDC vital signs. Asthma in the US. www.cdc.gov/vitalsigns/asthma/ (accessed 10/12/2012). ">CDC 2012</a>; <a href="./references#CD010758-bbs2-0060" title="Centers for Disease Control and Prevention. Trends in asthma prevalence, health care, and mortality in the United States, 2001‐2010. CDC. http://www.cdc.gov/nchs/data/databriefs/db94.htm (accessed 10/12/2012). ">CDCP 2011</a>). Considerable differences in asthma prevalence have been noted among different ethnic groups. Between 2008 and 2010, US rates were as follows: multiple‐race 14.1%, Alaskan Native 9.4%, American Indian 9.4%, black 11.2%, white 7.7% and Asian 5.2% (<a href="./references#CD010758-bbs2-0060" title="Centers for Disease Control and Prevention. Trends in asthma prevalence, health care, and mortality in the United States, 2001‐2010. CDC. http://www.cdc.gov/nchs/data/databriefs/db94.htm (accessed 10/12/2012). ">CDCP 2011</a>). The prevalence of wheezing symptoms in children varies geographically, with the UK having the highest recorded prevalence of current wheezing at 32.3%, and Ethiopia the lowest at 1.7% (<a href="./references#CD010758-bbs2-0078" title="PatelSP , JarvelinMR , LittleM . Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. Environmental Health2008;7:57. ">Patel 2008</a>). </p> <p>Asthma is associated with impaired quality of life (<a href="./references#CD010758-bbs2-0061" title="ClaytonS . Paediatric asthma: overcoming barriers to an improved quality of life. British Journal of Nursing2005; Vol. 14, issue 2:80–5. ">Clayton 2005</a>), and the condition presents financial implications (<a href="./references#CD010758-bbs2-0087" title="WuF , TakaroTK . Childhood asthma and environmental interventions. Environmental Health Perspectives2007;115(6):971–5. ">Wu 2007</a>). Each year, asthma exacerbations impact approximately 10 million people in the USA (<a href="./references#CD010758-bbs2-0067" title="KrishnanV , DietteGB , RandCS , BilderbackAL , MerrimanB , HanselNN , et al. Mortality in patients hospitalized for asthma exacerbations in the United States. American Journal of Respiratory and Critical Care Medicine2006;174(6):633‐8. ">Krishnan 2006</a>). Other countries report similarly high incidence rates; in the UK, more than 65,000 hospital admissions for asthma occurred in the period from 2005 to 2006 (<a href="./references#CD010758-bbs2-0074" title="NHS. NHS 2011 HES online hospital episode statistics. www.hesonline.nhs.uk (accessed 10/12/2012). ">NHS 2011</a>). Well‐recognised factors can be addressed to prevent hospital admissions in children with acute asthma (<a href="./references#CD010758-bbs2-0077" title="OrdonezG , PhelanP , OlinskyA , RobertsonCF . Preventable factors in hospital admissions for asthma. Archives of Disease in Childhood1998;78(2):143‐7. ">Ordonez 1998</a>). In recent years, evidence‐based clinical guidelines have emerged, at both national (e.g. <a href="./references#CD010758-bbs2-0057" title="BTS/SIGN2014 . British guideline on the management of asthma. A national clinical guideline. Revised 2014. http://www.sign.ac.uk/pdf/SIGN141.pdf (accessed 19/6/15)). ">BTS/SIGN 2014</a>; <a href="./references#CD010758-bbs2-0075" title="National Heart, Lung , and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR 3). http://www.nhlbi.nih.gov/health‐pro/guidelines/current/asthma‐guidelines (accessed 10/12/2012). ">NIH 2007</a>) and international (e.g. <a href="./references#CD010758-bbs2-0064" title="Global Initiative for Asthma(GINA) . From the global strategy for asthma management and prevention, global initiative for asthma (GINA) 2015. http://www.ginasthma.org/documents/4 (accessed 19/6/15). ">GINA 2015</a>) levels, to provide guidance for the management of asthma. Asthma is a consequence of airways inflammation, but with appropriate clinical management, health‐related quality of life can be maintained for considerable periods (<a href="./references#CD010758-bbs2-0085" title="World Health Organization. Health topics: asthma. http://www.who.int/topics/asthma/en/ (accessed 13 September 2011). ">WHO 2011</a>). Mortality specifically associated with both asthma and asthma morbidity is a major health concern (<a href="./references#CD010758-bbs2-0056" title="BramanSS . The global burden of asthma. Chest2006;130(1 Suppl):4S‐12S. ">Braman 2006</a>). </p> </section> <section id="CD010758-sec-0025"> <h3 class="title" id="CD010758-sec-0025">Description of the intervention</h3> <p>Asthma is a chronic inflammatory disorder of the airways that is characterised by reversible airways obstruction. A combination of inhaled corticosteroid (ICS) and long‐acting beta<sub>2</sub>‐agonist (LABA) is recommended for patients at step three of the British Thoracic Society guidelines, that is, patients not controlled by ICS alone. Evidence suggests that addition of a LABA to ICS alone can lead to improved lung function, improved symptoms, reduced use of rescue medications and reduced asthma exacerbations among patients with uncontrolled symptoms (<a href="./references#CD010758-bbs2-0057" title="BTS/SIGN2014 . British guideline on the management of asthma. A national clinical guideline. Revised 2014. http://www.sign.ac.uk/pdf/SIGN141.pdf (accessed 19/6/15)). ">BTS/SIGN 2014</a>). Although generally less effective, the combination of ICS and a leukotriene antagonist (LTRA) is a valid alternative to ICS combined with LABA (<a href="./references#CD010758-bbs2-0070" title="MontuschiP . Leukotrienes, antileukotrienes and asthma. Mini Reviews in Medicinal Chemistry2008;8(7):647‐56. ">Montuschi 2008</a>; <a href="./references#CD010758-bbs2-0071" title="MontuschiP , Peters‐GoldenML . Leukotriene modifiers for asthma treatment. Clinical and Experimental Allergy2010;40(12):1732‐41. ">Montuschi 2010</a>). </p> <p>Inhaled corticosteroids are fundamental in the treatment of asthma, and fluticasone furoate (FF) belongs to this class of drugs. Inhaled corticosteroids work by reducing inflammation and airway hyper‐responsiveness (<a href="./references#CD010758-bbs2-0053" title="BarnesPJ . Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. Journal of Allergy and Clinical Immunology1998;101(4):S427‐33. ">Barnes 1998</a>), thus improving symptoms of asthma and lung function (<a href="./references#CD010758-bbs2-0072" title="MontuschiP , BarnesPJ . New perspectives in pharmacological treatment of mild persistent asthma. Drug Discovery Today2011;16(23‐24):1084‐91. ">Montuschi 2011</a>). Most available ICS' are administered twice‐daily, and studies have shown that once‐daily use is less effective and leads to an increase in the requirement for rescue medication (<a href="./references#CD010758-bbs2-0057" title="BTS/SIGN2014 . British guideline on the management of asthma. A national clinical guideline. Revised 2014. http://www.sign.ac.uk/pdf/SIGN141.pdf (accessed 19/6/15)). ">BTS/SIGN 2014</a>; <a href="./references#CD010758-bbs2-0083" title="WeinerP , WeinerM , AzgadY . Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Thorax1995;50(12):1270‐3. ">Weiner 1995</a>). </p> <p>Vilanterol (VI) is a new drug that belongs to the LABA class. It has a rapid onset of action in experimental models and a 24‐hour duration of bronchodilating effects in patients with asthma (<a href="./references#CD010758-bbs2-0063" title="FusoL , MoresS , ValenteM , MelerbaM , MontuschiP . Long‐acting beta‐agonists and their association with inhaled corticosteroids in COPD. Current Medicinal Chemistry2013;20(12):1477‐95. ">Fuso 2013</a>). Long‐acting beta<sub>2</sub>‐agonist therapy added to ICS treatment in asthma has been shown to improve lung function, reduce asthma symptoms and decrease exacerbation rates (<a href="./references#CD010758-bbs2-0080" title="RemingtonTL , DiGiovineB . Long‐acting beta 2‐agonists: anti‐inflammatory properties and synergy with corticosteroids in asthma. Current Opinion in Pulmonary Medicine2005;11(1):74‐8. ">Remington 2005</a>). Available LABAs licensed for the treatment of patients with asthma require twice‐daily administration. Indacaterol and olodaterol are approved for chronic obstructive pulmonary disease (COPD) and require once‐daily administration.  </p> <p>At the present time, several combination inhalers containing both ICS and LABA are available for the treatment of adults with asthma. However, all of these involve twice‐daily dosing, which is less convenient for patients and leads to reduced adherence with long‐term therapy. Clinicians anticipate that providing a once‐daily combination inhaler would lead to increased adherence with treatment long‐term among people with asthma.  </p> <p>Investigators have provided few data on once‐daily combination treatments other than VI and FF for asthma. A 12‐week randomised controlled double‐blind study of 531 children aged six to 15 years showed that taking a single inhaler containing budesonide and formoterol once‐daily maintained pulmonary function, but taking the same inhaler twice‐daily resulted in improved pulmonary function, fewer discontinuations for worsening asthma and less need for daytime rescue medication (<a href="./references#CD010758-bbs2-0062" title="EidNS , NoonanMJ , ChippsB , ParasuramanB , MillerC , O’BrienCD . Once‐ vs twice‐daily budesonide/formoterol in 6‐ to 15‐year‐old patients with stable asthma. Pediatrics2010;126(3):e565‐75. ">Eid 2010</a>). Once‐daily budesonide/formoterol has shown improved asthma control when compared with once‐daily budesonide alone (at a four times higher dose) in children four to 11 years of age (<a href="./references#CD010758-bbs2-0054" title="BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. ">Bisgaard 2006</a>). </p> </section> <section id="CD010758-sec-0026"> <h3 class="title" id="CD010758-sec-0026">How the intervention might work</h3> <p>Inhaled corticosteroids serve as the cornerstone of asthma treatment and are initiated when patients require use of short‐acting ‘reliever’ medications on a regular basis. As well as the benefits mentioned previously, patients who are compliant with ICS therapy demonstrate a reduction in asthma exacerbations and in mortality related to asthma (<a href="./references#CD010758-bbs2-0079" title="PowellH , GibsonPG . Inhaled corticosteroid doses in asthma: an evidence‐based approach. Medical Journal of Australia2003;178(5):223‐5. ">Powell 2003</a>). It is well recognised that poor adherence is a major issue among patients with poorly controlled symptoms (<a href="./references#CD010758-bbs2-0057" title="BTS/SIGN2014 . British guideline on the management of asthma. A national clinical guideline. Revised 2014. http://www.sign.ac.uk/pdf/SIGN141.pdf (accessed 19/6/15)). ">BTS/SIGN 2014</a>). One of the issues that may contribute to this is the twice‐daily dosing regimen of most ICS'. </p> <p>Fluticasone furoate is a relatively new long‐acting ICS. It remains active for at least 24 hours after administration. Early studies have shown improvement in lung function tests and a favourable safety and tolerability profile (<a href="./references#CD010758-bbs2-0055" title="BleeckerER , BatemanED , BusseWW , LotvallJ , WoodcockA , FrithL , et al. Consistently favourable safety profile of fluticasone furoate (FF), a once‐daily (OD) inhaled corticosteroid (ICS), across a range of treatment steps in patients with uncontrolled asthma. American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011. ">Bleecker 2011</a>; <a href="./references#CD010758-bbs2-0086" title="WoodcockA , BatemanED , BusseWW , LötvallJ , SnowiseNG , ForthR , et al. Efficacy in asthma of once‐daily treatment with fluticasone furoate: a randomized, placebo controlled trial. Respiratory Research2011;12(1):132. ">Woodcock 2011</a>). </p> <p>In recent years, investigators have provided increasing evidence for the addition of LABAs to ICS therapy for the treatment of patients with asthma, and the benefit appears to consist of more than bronchodilatation alone. The action of corticosteroids is mediated by cytoplasmic glucocorticoid receptors (GRs); after binding with corticosteroids, GRs translocate to the nucleus, where they are able to regulate gene expression (<a href="./references#CD010758-bbs2-0072" title="MontuschiP , BarnesPJ . New perspectives in pharmacological treatment of mild persistent asthma. Drug Discovery Today2011;16(23‐24):1084‐91. ">Montuschi 2011</a>). Long‐acting beta<sub>2</sub>‐agonists have also been shown to induce GR nuclear translocation, although not as effectively as glucocorticoids. Study of sputum epithelial cells and macrophages of people with asthma has shown that the LABA, salmeterol, given in combination with fluticasone propionate (FP), was more effective than low‐dose FP alone in enhancing GR nuclear translocation (<a href="./references#CD010758-bbs2-0082" title="UsmaniOS , ItoK , ManeechotesuwanK , ItoM , JohnsonM , BarnesPJ , et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Amercian Journal of Respiratory and Critical Care Medicine2005;172(6):704‐12. ">Usmani 2005</a>). </p> <p>Interleukin‐8 (IL‐8) is a chemokine that has been implicated in the abnormal airway inflammation seen in patients with asthma; studies have shown that study participants with clinically stable asthma have higher levels of IL‐8 in bronchoalveolar lavage samples than normal healthy control participants (<a href="./references#CD010758-bbs2-0076" title="NockerRE , SchoonbroodDF , van deGraafEA , HackCE , LutterR , JansenHM , et al. Interleukin‐8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. International Archives of Allergy and Immunology1996;109(2):183‐91. ">Nocker 1996</a>). A study looking at IL‐8 production from neutrophils stimulated by cigarette smoke reported that salmeterol and FP additively suppressed IL‐8 release from neutrophils when compared with either agent alone. This effect is not seen in all human cell types and appears to be cell‐specific. The mechanism of action is not yet clear, but researchers have suggested that increased translocation of GRs to the nucleus may be involved (<a href="./references#CD010758-bbs2-0073" title="MortazE , RadMV , JohnsonM , RaatsD , NijkampFP , FolkertsG . Salmeterol with fluticasone enhances the suppression of IL‐8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. Journal of Molecular Medicine2008;86(9):1045–56. ">Mortaz 2008</a>). </p> <p>For patients whose condition is uncontrolled by regular ICS therapy, current British Thoracic Society (BTS) guidelines recommend the addition of a LABA, such as salmeterol or formoterol (<a href="./references#CD010758-bbs2-0057" title="BTS/SIGN2014 . British guideline on the management of asthma. A national clinical guideline. Revised 2014. http://www.sign.ac.uk/pdf/SIGN141.pdf (accessed 19/6/15)). ">BTS/SIGN 2014</a>). Both of these medications have a twice‐daily dosing regimen that affects adherence and, therefore, asthma control. Long‐acting beta<sub>2</sub>‐agonists are of benefit because of their bronchodilation effect, and VI is a new selective beta<sub>2</sub>‐agonist within this class (<a href="./references#CD010758-bbs2-0058" title="CazzolaM , CalzettaL , MateraMG . b2‐adrenoceptor agonists:current and future direction. British Journal of Pharmacology2011;163(1):4‐17. ">Cazzola 2011</a>). It has been shown that VI is well tolerated with no significant adverse effects (<a href="./references#CD010758-bbs2-0066" title="KempsfordR , NorrisV , SiedererS . Vilanterol trifenatate, a novel inhaled long‐acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulmonary Pharmacology and Therapeutics2013;26(2):256‐64. ">Kempsford 2013</a>), and that it leads to an increase in symptom‐free periods and a reduction in the use of rescue medication (<a href="./references#CD010758-bbs2-0069" title="LotvallJ , BatemanED , BleeckerER , BusseWW , WoodcockA , FollowseR , et al. 24‐Hour duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. European Respiratory Journal2012;40(3):570–9. ">Lotvall 2012</a>). </p> <p>In summary, limited studies suggest that effective once‐daily ICS and LABA therapy would allow a once‐daily dosing regimen (e.g. <a href="./references#CD010758-bbs2-0068" title="KunaP , CreemersJP , VondraV , BlackPN , LindqvistA , NihlenU , et al. Once‐daily dosing with budesonide/formoterol compared with twice‐daily budesonide/formoterol and once‐daily budesonide in adults with mild to moderate asthma. Respiratory Medicine2006;100(12):2151‐9. ">Kuna 2006</a>), leading to the possibility of increased adherence and improved asthma control in adults and in children. </p> </section> <section id="CD010758-sec-0027"> <h3 class="title" id="CD010758-sec-0027">Why it is important to do this review</h3> <p>Published randomised trials have examined use of VI and FF in combination. This review aims to establish whether VI combined with FF may play a positive role in the management of chronic asthma among children and adults. This is important to determine, as a VI/FF combination would consist of a once‐daily medication. This dosing regimen may lead to increased medication adherence, improved health‐related quality of life (HRQoL) and reduced asthma exacerbations and symptoms. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010758-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010758-sec-0028"></div> <p>To compare effects of VI and FF in combination versus placebo, or versus other ICSs and/or LABAs, on acute exacerbations and on HRQoL in adults and children with chronic asthma. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010758-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010758-sec-0029"></div> <section id="CD010758-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010758-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) reported as full text, those published as abstract only and unpublished data. </p> </section> <section id="CD010758-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies involving adults and children with a diagnosis of asthma. We excluded participants with the following co‐morbidities: co‐existing chronic disease such as smoking‐related COPD, congenital heart disease and diseases such as cystic fibrosis and chronic renal failure. We also excluded people who are current smokers and pregnant women. </p> </section> <section id="CD010758-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We planned to include studies comparing the following interventions.</p> <p> <ul id="CD010758-list-0001"> <li> <p>VI and FF versus placebo.</p> </li> <li> <p>VI and FF versus ICS and required short‐acting beta<sub>2</sub>‐agonist (SABA). </p> </li> <li> <p>VI and FF versus other combination inhalers.</p> </li> <li> <p>VI and FF versus ICS and LABA in separate inhalers.</p> </li> </ul> </p> <p>We also planned to include the following co‐interventions, provided they were not part of the randomised treatment: bronchodilators, systemic steroids, leukotriene antagonists, oral aminophylline and macrolide antibiotics. </p> </section> <section id="CD010758-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010758-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010758-list-0002"> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroids (OCS) </p> </li> <li> <p>Serious adverse event*.</p> </li> </ul> </p> </section> <section id="CD010758-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010758-list-0003"> <li> <p>Measures of lung function: forced expiratory flow in one second (FEV<sub>1</sub>), peak expiratory flow (PEF). </p> </li> <li> <p>Asthma symptoms.</p> </li> <li> <p>Adverse events/side effects.</p> </li> </ul> </p> <p>A study report describing one or more of the outcomes listed here was not an inclusion criterion for the review. </p> <p>*Defined as any adverse event or adverse reaction that results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation or results in persistent or significant disability or incapacity. </p> </section> </section> </section> <section id="CD010758-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010758-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified studies by searching the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Information Specialist for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED) and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD010758-sec-0138">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy presented in <a href="./appendices#CD010758-sec-0144">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>). We searched all databases from their inception to 24 June 2016, and we imposed no restriction on language of publication. </p> </section> <section id="CD010758-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We searched relevant manufacturers' websites for trial information. </p> <p>We searched on 24 June 2015 for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). </p> </section> </section> <section id="CD010758-sec-0040"> <h3 class="title" id="CD010758-sec-0040">Data collection and analysis</h3> <section id="CD010758-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LB, NW) independently screened the titles and abstracts of all studies identified for possible inclusion as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved full‐text study reports/publications, and two review authors (LB, NW) independently screened the full text, identified studies for inclusion and identified and recorded reasons for exclusion of ineligible studies. We planned to resolve disagreements through discussion or, if required, by consultation with a third review author (CP); however, this was not necessary. We identified and excluded duplicates and collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) flow diagram (<a href="#CD010758-fig-0001">Figure 1</a>) and entered data regarding all studies into the <a href="./references#CD010758-sec-0153" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD010758-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010758-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010758-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form that had been piloted on at least one study in the review to record study characteristics and outcome data. Two review authors (CP, SJM) extracted study characteristics from reports of included studies. We extracted the following study characteristics. </p> <p> <ul id="CD010758-list-0004"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study settings, withdrawals and date of study. </p> </li> <li> <p>Participants: number (N), mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected and time points reported.</p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (CP, SJM) independently extracted outcome data from the included studies. We noted in the <a href="./references#CD010758-sec-0153" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way. We planned to resolve disagreements by consensus or by consultation with a third review author (NW); however, this was not necessary. One review author (KD) transferred data into the Review Manager (<a href="./references#CD010758-bbs2-0081" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) file. We double‐checked that data were entered correctly by comparing data presented in the systematic review with those provided in study reports. A second review author (SJM) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD010758-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CP, SJM) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010758-bbs2-0065" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). We planned to resolve disagreements by discussion or by consultation with another review author (KD); however, this was not necessary. We assessed risk of bias according to the following domains. </p> <p> <ul id="CD010758-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low or unclear, and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different than for a patient‐reported pain scale). When information on risk of bias was related to unpublished data or to correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering each treatment effect,we took into account the risk of bias for studies that contributed to that outcome. </p> <section id="CD010758-sec-0044"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to this published protocol and reported any deviations from it in the <a href="#CD010758-sec-0151">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD010758-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to analyse dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) or standardised mean differences (SMDs), and to present them with 95% confidence intervals (CIs). We entered data presented as a scale with a consistent direction of effect. </p> <p>We undertook meta‐analyses only when data were available, and when it was meaningful to do so (i.e. when treatments, participants and the underlying clinical question were similar enough for pooling to make sense). </p> <p>We will narratively describe skewed data reported as medians and interquartile ranges if reported for future updates of this review. </p> <p>When a single trial reported multiple trial arms, we included only the relevant arms.</p> </section> <section id="CD010758-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>We identified cross‐over trials and sought data for a paired analysis from the trial report or study authors to appropriately include data in the review using the inverse variance method. However, this was unsuccessful, and we provided the data in additional tables. We identified no cluster‐randomised trials, but future versions of this review will analyse data at the level of the individual while allowing for clustering in the data by using the intracluster correlation co‐efficient. If this is not reported in the trial, we will impute it from similar studies. </p> </section> <section id="CD010758-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>We planned to contact investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study is identified as abstract only) when uncertainties arise during completion of the study. In practice for this review, we had to do this with only one of the study authors. </p> </section> <section id="CD010758-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We visually assessed statistical heterogeneity between studies by inspecting forest plots and using the Chi<sup>2</sup> test (P value &lt; 0.1 was considered significant owing to the low power of the test). We calculated the I<sup>2</sup> statistic, which describes the percentage of variability in effect estimates that is due to heterogeneity rather than to sampling error (chance). Values of I<sup>2</sup> range from 0 to 100, with 0 representing no heterogeneity and 100 representing considerable heterogeneity. </p> <p>For this review:</p> <p> <ul id="CD010758-list-0006"> <li> <p>0% to 40%: Heterogeneity might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: shows considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD010758-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>If we cannot pool more than 10 studies for a future update of this review, we will create and examine a funnel plot to explore possible small‐study biases and publication bias. </p> </section> <section id="CD010758-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model and performed a sensitivity analysis with a random‐effects model when heterogeneity was substantial. </p> <p>We will combine data on outcomes at six months and at 12 months in future versions of this review if sufficient data become available. We will describe other time points when data become available. </p> <section id="CD010758-sec-0051"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table by using the following outcomes.</p> <p> <ul id="CD010758-list-0007"> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Asthma exacerbation as defined by hospital admission or treatment with a course of OCS. </p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Adverse events/side effects.</p> </li> </ul> </p> <p>We used the five GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to studies that contribute data to the meta‐analyses for pre‐specified outcomes. We followed the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010758-bbs2-0065" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) and used GRADEpro software. We justified all decisions to downgrade or upgrade the quality of studies by using footnotes; we included comments to aid the reader's understanding of the review when necessary. </p> </section> </section> <section id="CD010758-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ul id="CD010758-list-0008"> <li> <p>Age (nought to five years, six to 16 years, 16 plus years).</p> </li> </ul> </p> <p>We planned to use the following outcomes in subgroup analyses.</p> <p> <ul id="CD010758-list-0009"> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Asthma symptoms.</p> </li> </ul> </p> <p>We planned to use the formal test for subgroup interactions in Review Manager (<a href="./references#CD010758-bbs2-0081" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), but sufficient data were not available. </p> </section> <section id="CD010758-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses, but sufficient data were not available. </p> <p> <ul id="CD010758-list-0010"> <li> <p>Excluding studies with an overall high risk of bias.</p> </li> <li> <p>Excluding cross‐over trials and cluster‐randomised trials.</p> </li> <li> <p>Using a random‐effects model.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010758-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010758-sec-0054"></div> <section id="CD010758-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD010758-sec-0056"> <h4 class="title">Results of the search</h4> <p>We identified 29 records through electronic searches conducted in October 2013, and we identified 15 similar records in October 2014, together with eight additional records in October 2015 and an additional nine in June 2016, yielding a total of 59 records obtained from electronic searches. Additional searches from trial registries provided 20 additional records (<a href="#CD010758-fig-0001">Figure 1</a>). </p> <p>Thirty‐eight records (representing 14 studies) met our criteria for inclusion; we have described these in the <a href="./references#CD010758-sec-0153" title="">Characteristics of included studies</a> table. </p> <p>We excluded 29 records (representing 20 studies) and listed our reasons for exclusion in the <a href="./references#CD010758-sec-0154" title="">Characteristics of excluded studies</a> table. </p> <p>We identified 12 ongoing studies and provided details of these studies in the <a href="./references#CD010758-sec-0155" title="">Characteristics of ongoing studies</a> table. </p> </section> <section id="CD010758-sec-0057"> <h4 class="title">Included studies</h4> <p>In all, 14 studies met our criteria for inclusion, with a total of 6641 randomised participants, of whom 5638 completed the study (<a href="./references#CD010758-sec-0153" title="">Characteristics of included studies</a>). Eight of these studies included both adolescents and adults (12 years of age and older): <a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a>; <a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a>; <a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a>; <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>; <a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a>. Five studies recruited only adult participants (18 years of age and older): <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>; <a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>, and one study recruited only paediatric participants (between five and 11 years of age): <a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a>. </p> <p>We noted considerable variation in the range of comparisons presented in the eight studies that included both adolescents and adults (12 years of age and older). </p> <p> <ul id="CD010758-list-0011"> <li> <p>One compared FF/VI 100/25 mcg versus FF/VI 200/25 mcg versus placebo versus prednisolone (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>). </p> </li> <li> <p>One compared FF/VI 100/25 mcg versus FF 100 mcg (<a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a>). </p> </li> <li> <p>One compared FF/VI 100/25 mcg versus FF/VI 200/25 mcg and versus FF 100 mcg (<a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a>). </p> </li> <li> <p>One compared FF/VI 100/25 mcg versus FF 100 mcg and versus placebo (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>). </p> </li> <li> <p>One compared FF/VI 100/25 mcg versus FF/VI 200/25 mcg and versus FP 500 mcg (<a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a>). </p> </li> </ul> <ul id="CD010758-list-0012"> <li> <p>One compared FF/VI 200/25 mcg versus FP 500 mcg (<a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a>). </p> </li> <li> <p>One compared FF 200 mcg versus FF/VI 200/25 mcg and versus FP 500 mcg (<a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>). </p> </li> <li> <p>One compared FF/VI 100/25 mcg versus FP/salmeterol (SAL) 250/50 mcg (<a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a>). </p> </li> </ul> </p> <p>We observed similar variation in the range of comparisons presented in the five studies that included only adults. </p> <p> <ul id="CD010758-list-0013"> <li> <p>One compared FF/VI 100/25 versus FP/SAL500/50 (<a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>). </p> </li> <li> <p>One compared FF/VI 100/25 mcg AM versus FF/VI 100/25 mcg PM and versus placebo (<a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>). </p> </li> <li> <p>One compared FF 100 mcg versus FF/VI 100/25 mcg and versus placebo (<a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>). </p> </li> <li> <p>One compared FF 100 mcg versus FF/VI 100/25 mcg and versus umeclidinium (<a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a>). </p> </li> <li> <p>One compared FF/VI 100/25 mcg versus FF 100 mcg and versus placebo versus VI 25 mcg (<a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>). </p> </li> </ul> </p> <p>The study that included only children presented the following comparison.</p> <p> <ul id="CD010758-list-0014"> <li> <p>FF/VI 100/25 mcg versus FF 100 mcg (<a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a>). </p> </li> </ul> </p> <p>We have provided additional detailed information on the included studies in the <a href="./references#CD010758-sec-0153" title="">Characteristics of included studies</a> table and in <a href="#CD010758-tbl-0003">Table 1</a>. </p> <div class="table" id="CD010758-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (weeks) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity at baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility &gt; 12%</p> <p> </p> <p>FEV<sub>1</sub> &gt; 50% of predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Comply with treatment</p> <p> </p> <p>Clinical diagnosis of asthma for ≥ 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cortisol urinary excretion, serum AUC and trough</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 to 78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility &gt; 12%</p> <p> </p> <p>FEV<sub>1</sub> &gt; 50% to 90% of predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Using ICS</p> <p> </p> <p>History of ≥ 1 exacerbation requiring hospitalisation or steroids in the past year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility &gt; 12%</p> <p>FEV<sub>1</sub> 50% to 80% of predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS for &gt; 12 weeks before study</p> <p> </p> <p>&gt; 12 years of age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, not clear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 90% of predicted normal </p> <p>Reversibility FEV<sub>1</sub> ≥ 12% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS for 12 weeks before study</p> <p> </p> <p>&gt; 12 years of age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 90% of predicted normal </p> <p>Reversibility FEV<sub>1</sub> ≥ 12% </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Clinical diagnosis of asthma</p> <p> </p> <p>ICS at high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACT suggesting poor control and FEV<sub>1</sub> mean  70% (SD 11%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma ≥ 20 years of age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No, conference abstract only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 80% of predicted </p> <p>Demonstrated reversibility by ≥ 12%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for regular controller therapy for minimum of 8 weeks</p> <p>Stable dose of ICS for ≥ 4 weeks</p> <p>≥ 18 years of age</p> <p>Diagnosis of asthma for ≥ 6 months</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility of disease: demonstrated ≥ 12% and</p> <p>FEV<sub>1</sub> 40% to 90% </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS, with or without LABA, for ≥ 12 weeks</p> <p>Clinical diagnosis of asthma for 12 weeks</p> <p> </p> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> ≥ 60% of predicted. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 and 70 years of age inclusive</p> <p>Using an ICS, with or without a SABA, for ≥ 12 weeks before screening</p> <p>Participants who are current non‐smokers, who have not used inhaled tobacco products in the 12‐month period preceding screening visit </p> <p>Body weight ≥ 50 kg and BMI within the range 19.0 to 29.9 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, details not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 90% of predicted </p> <p>Reversibility FEV<sub>1</sub> ≥ 12% </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Current asthma therapy that includes an ICS for ≥ 12 weeks before first visit</p> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cortisol, ECG, mouth swabs, various blood parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate (GINA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stable asthma therapy (FP, total daily dose ≤ 400 mcg or equivalent) and SABA inhaler for ≥ 4 weeks before screening </p> <p>5 to 12 years of age</p> <p>Clinical diagnosis of asthma 6 months before</p> <p>Controlled asthma (Childhood ACT &gt; 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> &gt; 70% of predicted at screening </p> <p> </p> <p>Methacholine challenge PC20 &lt; 8 mg/mL at screening</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Stable asthma therapy (FP, total daily dose ≤ 400 mcg or equivalent) and SABA inhaler for ≥ 4 weeks before screening </p> <p>BMI within the range 18.5 to 35.0 kg/m<sup>2</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 with 3 weeks' washout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> &gt; 70% of predicted at screening </p> <p> </p> <p>Methacholine challenge PC20 &lt; 8 mg/mL at screening</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stable asthma therapy (FP, total daily dose ≤ 400 mcg or equivalent) and SABA inhaler for ≥ 4 weeks before screening </p> <p>BMI within the range 18.5 to 35.0 kg/m<sup>2</sup> </p> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility ≥ 12% and 200 mL within 10 to 40 minutes following 2 to 4 inhalations of albuterol </p> <p>FEV<sub>1</sub> 40% to 85% predicted normal </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Currently using ICS therapy</p> <p>Clinical diagnosis of asthma</p> <p>Adults  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACT: Asthma Control Test</p> <p>AUC: area under the curve</p> <p>BMI: body mass index</p> <p>ECG: electrocardiogram</p> <p>FEV<sub>1</sub>: forced expiratory volume in one second </p> <p>FP: fluticasone propionate</p> <p>GINA: Global Initiative for Asthma</p> <p>ICS: inhaled corticosteroid</p> <p>LABA: long‐acting beta<sub>2</sub>‐agonist </p> <p>PC20: provocative concentration of methacholine estimated to result in a 20% reduction in FEV<sub>1</sub> </p> <p>SABA: short‐acting beta<sub>2</sub>‐agonist </p> </div> </div> </section> <section id="CD010758-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies for the following reasons: Participants in the study did not have a diagnosis of asthma (N = 9, 45%); the ICS used in the study was not FF (N = 3, 15%); pooled analysis included data from the clinical trials (N = 2, 10%); study was withdrawn before participants were enrolled (N = 1, 5%); VI and FF were not used together in the intervention arm (N = 1, 5%); focus of trial was on VI and FP, not on VI and FF (N = 1, 5%) and evaluation of dry powder inhaler (DPI) (N = 1, 5%); trial compared budesonide/formoterol maintenance and reliever therapy versus FF/VI (N = 1, 5%); and study evaluated exhaled nitric oxide time profile as a biomarker of airway Inflammation (N = 1, 5%) (<a href="./references#CD010758-sec-0154" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD010758-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD010758-sec-0060"> <h4 class="title">Allocation</h4> <p>We judged 12 of the included studies to be at low risk with respect to selection bias. We considered risk of selection bias in the two remaining studies (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>) to be unclear (<a href="#CD010758-fig-0002">Figure 2</a>; <a href="#CD010758-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD010758-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010758-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010758-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010758-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD010758-sec-0061"> <h4 class="title">Blinding</h4> <p>For blinding, we judged 12 of the included studies to be at low risk. For <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> and <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>, we judged the risk to be unclear (<a href="#CD010758-fig-0002">Figure 2</a>; <a href="#CD010758-fig-0003">Figure 3</a>). </p> </section> <section id="CD010758-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>For attrition bias, we judged 12 of the included studies to have low risk. We considered risk of selection bias in the two remaining studies (<a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) to be unclear (<a href="#CD010758-fig-0002">Figure 2</a>; <a href="#CD010758-fig-0003">Figure 3</a>). </p> </section> <section id="CD010758-sec-0063"> <h4 class="title">Selective reporting</h4> <p>For reporting bias, we judged 13 studies to be at low risk of bias; for <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>, we judged this risk to be unclear (<a href="#CD010758-fig-0002">Figure 2</a>; <a href="#CD010758-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD010758-sec-0064"> <h3 class="title" id="CD010758-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD010758-tbl-0001"><b>Summary of findings for the main comparison</b> Vilanterol and fluticasone furoate compared with placebo for asthma</a> </p> <section id="CD010758-sec-0065"> <h4 class="title">VI and FF 100/25 mcg versus placebo</h4> <section id="CD010758-sec-0066"> <h5 class="title">Primary outcomes</h5> <section id="CD010758-sec-0067"> <h6 class="title">Health‐related quality of life</h6> <p>See <a href="#CD010758-tbl-0004">Table 2</a>. </p> <div class="table" id="CD010758-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Health‐related quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>score (change from baseline)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 100/25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL 250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>AQLQ change from baseline at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.91 (0.055),</b> </p> <p><b>n = 180</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.76 (0.055),</b> </p> <p><b>n = 184</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61 (0.061),</b> </p> <p><b>n = 149</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.15 (0.00 to 0.30), 0.30 (0.14 to 0.46), 0.15 (‐0.01 to 0.31)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>AQLQ change from baseline at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.80 (0.069),</b> </p> <p><b>n = 140</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.69 (0.074),</b> </p> <p><b>n = 123</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12 (‐0.08 to 0.32)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>AQLQ change from baseline at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.061),</b> </p> <p><b>n = 154</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.056),</b> </p> <p><b>n = 180</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.059),</b> </p> <p><b>n = 163</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.08 (‐0.24 to 0.08), ‐0.08 (‐0.25 to 0.09), 0.00 (‐0.16 to 0.16)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>AQLQ change from baseline at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.88 (0.071),</b> </p> <p><b>n = 140</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.93 (0.065),</b> </p> <p><b>n = 167</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.90 (0.068),</b> </p> <p><b>n = 156</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.05 (‐0.24 to 0.14), ‐0.02 (‐0.21 to 0.17), 0.03 (‐0.15 to 0.21)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>AQLQ change from baseline at 168 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46 (0.043),</b> </p> <p><b>n = 342</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.37 (0.043), n = 335</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09 (‐0.03 to 0.21)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>EQ‐5D change from baseline at 168 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.5 (0.60),</b> </p> <p><b>n = 343</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.1 (0.60), n = 349</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.4 (‐0.3 to 3.0)</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AQLQ: asthma quality of life questionnaire; CI: confidence interval; EQ‐5D: EuroQuality of Life‐5D questionnaire; FF: fluticasone furoate; FP: fluticasone propionate; MD: mean difference; SAL: salmeterol; SE: standard error; VI: vilanterol </p> </div> </div> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> provided data on the change in quality of life (as measured by the Asthma Quality of Life Questionnaire (AQLQ) at 12 weeks), indicating a significant difference in favour of VI and FF 100/25 mcg (mean difference (MD) 0.30, 95% confidence interval (CI) 0.14 to 0.46; <a href="./references#CD010758-fig-0004" title="">Analysis 1.1</a>). The minimal important difference on this scale is 0.5 unit. </p> </section> <section id="CD010758-sec-0068"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p>See <a href="#CD010758-tbl-0005">Table 3</a>. </p> <div class="table" id="CD010758-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Asthma exacerbation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF </b> </p> <p><b>200 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>200/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL</b> </p> <p><b>250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP </b> </p> <p><b>500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prednisolone </b> </p> <p><b>10 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a><sup>a</sup> </p> <p>6 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/15 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/58 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥ 24 to 78 weeks' duration</p> <p>Time to first severe exacerbation (HR 0.80, 95% CI 0.64 to 0.99). Annualised rate of severe exacerbation 25% reduction (95% CI 5% to 40%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>154/1009 (15.26%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>186/1010 (18.42%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> <p>52 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/201 (1.49%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6/202 (2.97%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/100 (3.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/155 (0.65%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/154 (1.95%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period between periods </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/24 (0.00%) AM</b> </p> <p><b>0/25 (0.00%) PM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/23 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a><sup>b</sup> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/403 (0.25%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2/403 (0.50%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>One participant in the FF/VI 100/25 mcg group experienced a severe asthma exacerbation concurrent with sinusitis and was withdrawn owing to lack of efficacy. The participant did not require hospitalisation, and the event, which was not classified as an AE, resolved following treatment with prednisone </p> <p><sup>b</sup>The incidence of asthma exacerbations was low, and no difference was noted between groups (3% vs 2% on FP/SAL vs FF/VI, respectively (on‐treatment events)). Eight (2%) participants in the FF/VI group and seven (2%) in the FP/SAL group withdrew because of exacerbation. One patient in the FF/VI group and two in the FP/SAL group were hospitalised because of exacerbation </p> <p>AM: morning; CI: confidence interval; FF: fluticasone furoate; FP: fluticasone propionate; HR: hazard ratio; PM: afternoon; SAL: salmeterol; VI: vilanterol </p> </div> </div> <p>No exacerbations were reported in the VI and FF 100/25 mcg or placebo arms in the two short‐term trials (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) pooled in <a href="./references#CD010758-fig-0005" title="">Analysis 1.2</a>. </p> </section> <section id="CD010758-sec-0069"> <h6 class="title">Serious adverse events</h6> <p>See <a href="#CD010758-tbl-0006">Table 4</a>. </p> <div class="table" id="CD010758-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF </b> </p> <p><b>200 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>200/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VI 25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL</b> </p> <p><b>250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prednisolone </b> </p> <p><b>10 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> </p> <p>6 weeks' duration. Post‐treatment period SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/15 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/58 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥ 24 to 78 weeks' duration. On‐treatment SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41/1009 (4.06%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29/1010 (2.87%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4/346 (1.16%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/347 (0.86%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/346 (0.29%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/201 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/205 (0.49%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/203 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> <p>52 weeks' duration. On‐treatment SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/201 (1.49%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/202 (0.50%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7/100 (7.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>Cross‐over trial. Three of 7 treatments (2 weeks) separated by 12 to 14‐day washout periods </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/172</b> </p> <p><b>(0.006%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/187</b> </p> <p><b>(0%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/155 (0.65%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2/154 (1.30%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/24 (0.00%) AM.</b> </p> <p><b>0/25 (0.00%) PM.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/23 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/194 (0.52%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6/197 (3.05%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2/195 (1.03%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a> </p> <p>Cross‐over trial. 11 weeks (for a single period)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/25 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/25 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a><sup>a</sup> </p> <p>Cross‐over trial. 28 days for each period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/51 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/51 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/51 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> <p>Cross‐over trial. 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/27 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/27 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/26 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/27 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4/403 (0.99%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5/403 (1.24%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The main paper reports that 1 of the 52 withdrew during the study owing to an SAE, which occurred 4 days after the last dose in the FF 100 treatment period. This participant was provisionally diagnosed with moderate (grade 2) Still’s disease. Six weeks later, the participant was hospitalised. A diagnosis of histiocytic necrotising lymphadenitis (Kikuchi’s disease) was made on the basis of histology of an excised lymph node. Tapered prednisolone treatment, initiated at 60 mg per day, has been successful </p> <p>FF: fluticasone furoate; FP: fluticasone propionate; SAE: serious adverse event; SAL: salmeterol; VI: vilanterol </p> </div> </div> <p>No serious adverse events were observed in the VI and FF 100/25 mcg or placebo arms in the five studies (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) aggregated in <a href="./references#CD010758-fig-0006" title="">Analysis 1.3</a>. These studies were of short duration; the longest (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>) had a treatment period of 12 weeks. </p> </section> </section> <section id="CD010758-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD010758-sec-0071"> <h6 class="title">Measures of lung function: forced expiratory flow in one second (FEV<sub>1</sub>), peak expiratory flow (PEF) </h6> <p>See <a href="#CD010758-tbl-0007">Table 5</a>; <a href="#CD010758-tbl-0008">Table 6</a>. </p> <div class="table" id="CD010758-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Forced expiratory flow in one second (FEV1)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>measure</b> </p> <p><b>time point/</b> </p> <p><b>duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> <p><b>Mean (SE), N, of MD (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VI 25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL250/50 mcg twice‐daily</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI, unless otherwise stated)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>Trough FEV<sub>1</sub> </p> <p>At 0 to 12 weeks</p> <p>Change in baseline trough FEV<sub>1</sub> from baseline to week 12 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.441 L (0.022)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.365 L (0.022)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.457 L (0.022)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>Trough FEV<sub>1</sub> </p> <p>At 0 to 12 weeks</p> <p>Mean change in trough FEV<sub>1</sub> (pre‐bronchodilator and pre‐dose) from baseline to </p> <p>week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.368 L (0.0304),</b> </p> <p><b>n = 200</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.332 L (0.0302),</b> </p> <p><b>n = 203</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.196 L (0.0310),</b> </p> <p><b>n = 193</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 L (‐0.05 to 0.12) 0.17 L (0.09 to 0.26) 0.14 L (0.05 to 0.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>Trough FEV<sub>1</sub> combining all treatment periods </p> <p>At 0 to 2 weeks</p> <p>3 of 7 treatments (2 weeks) separated by 12 to 14‐day washout periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.200 L,</b> </p> <p><b>n = 158</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.087 L,</b> </p> <p><b>n = 158</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted treatment difference 0.108 L (0.040 to 0.176)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Weighted mean FEV<sub>1</sub> over the day </p> <p>At day 14</p> <p>Weighted mean FEV<sub>1</sub>, over 0 to 24 hours post dose at day 14 </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose: 3.188 L</b> <br/> <b>(3.112 to 3.265), n = 24</b> </p> <p><b>PM dose: 3.233 L</b> <br/> <b>(3.159 to 3.306), n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.811 L</b> <br/> <b>(2.729 to 2.893),</b> </p> <p><b>n = 20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 0.377 L (90% CI 0.293 to 0.462)</p> <p>PM vs placebo 0.422 L (90% CI 0.337 to 0.507)</p> <p>AM vs PM ‐0.44 L</p> <p>(90% CI ‐0.125 to 0.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) </p> <p>Day 14 pre‐treatment (trough) AM FEV<sub>1</sub> </p> <p>At day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose: 3.191 L</b> <br/> <b>(3.087 to 3.295), n = 24</b> </p> <p><b>PM dose: 3.285 L</b> <br/> <b>(3.187 to 3.383),</b> </p> <p><b>n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.788 L</b> <br/> <b>(2.684 to 2.892),</b> </p> <p><b>n = 22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 0.403 L (90% CI 0.272 to 0.533)</p> <p>PM vs placebo 0.496 L (90% CI 0.369 to 0.624)</p> <p>AM vs PM ‐0.094 L (90% CI ‐0.221 to 0.034)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) </p> <p>Day 14 pre‐treatment (trough) PM FEV<sub>1</sub> </p> <p>At day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose</b> : <b>3.153 L</b> <br/> <b>(3.049 to 3.258), n = 24</b> </p> <p><b>PM dose: 3.188 L</b> <br/> <b>(3.088 to 3.288), n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.879 L</b> <br/> <b>(2.775 to 2.982),</b> </p> <p><b>n = 23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 0.275 L (90% CI 0.169 to 0.380)</p> <p>PM vs placebo 0.309 L (90% CI 0.205 to 0.413)</p> <p>AM vs PM ‐0.034</p> <p>(90% CI ‐0.138 to 0.070)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>Change in baseline trough FEV<sub>1</sub> </p> <p>At 24 weeks</p> <p>Change from baseline in clinic visit trough (pre‐bronchodilator and pre‐dose) FEV<sub>1</sub> at end of 24‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.201 L (0.0303),</b> </p> <p><b>n = 186</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.394 L (0.0302),</b> </p> <p><b>n = 187</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.183 L (0.0300),</b> </p> <p><b>n = 190</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.19 L (‐0.28 to ‐0.11) 0.02 L (‐0.06 to 0.10) 0.21 L (0.13 to 0.29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) </p> <p>Change from baseline in weighted mean serial FEV<sub>1</sub> over 24 hours </p> <p>At 24 weeks</p> <p>Change from baseline in weighted mean serial FEV<sub>1</sub> over 0 to 24 hours post dose at week 24 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.328 L (0.0493),</b> </p> <p><b>n = 83</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.464 L (0.0470),</b> </p> <p><b>n = 89</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.258 L (0.0483),</b> </p> <p><b>n = 86</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14 L (‐0.27 to ‐0.00) 0.07 L (‐0.07 to 0.21) 0.21 L (0.07, 0.34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a> </p> <p>23 hours post challenge</p> <p>At day 29</p> <p>Cross‐over trial ‐ 28 days for each period</p> <p>Weighted mean change from baseline in FEV<sub>1</sub> between 0 and 2 hours following 22 to 23‐hour post‐treatment allergen challenge at day 29 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.227 L (0.0550),</b> </p> <p><b>n = 46</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.210 L (0.0549),</b> </p> <p><b>n = 49</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.372 L (0.0557),</b> </p> <p><b>n = 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF vs placebo 0.162 L (0.087 to 0.237)</p> <p>FF/VI vs placebo 0.145 L (0.069 to 0.222)</p> <p>FF/VI vs FF ‐0.017 L (‐0.091 to 0.057)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>) </p> <p>Decrease from baseline 23 hours post challenge</p> <p>At day 29</p> <p>Maximum % decrease from baseline FEV<sub>1</sub> between 0 and 2 hours following 22 to 23‐hour post‐treatment allergen challenge at day 29 of each treatment period (time frame: baseline and at day 29 of each treatment period (up to study day 197)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐13.206% (2.0491),</b> </p> <p><b>n = 46</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐14.040% (2.0435),</b> </p> <p><b>n = 49</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐24.991% (2.0736),</b> </p> <p><b>n = 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF vs placebo 10.951% (8.053 to 13.848)<br/> FF/VI vs placebo 11.785% </p> <p>(8.849 to 14.721)<br/> FF/VI vs FF 0.834% (‐2.010 to 3.678) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>) </p> <p>Change from baseline FEV<sub>1</sub> </p> <p>23 hours post challenge</p> <p>Minimum FEV<sub>1</sub> absolute change from baseline between 0 and 2 hours following 22 to 23‐hour post‐treatment allergen challenge at day 29 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.478 L (0.0767),</b> </p> <p><b>n = 46</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.479 L (0.0765),</b> </p> <p><b>n = 49</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.809 L (0.0775),</b> </p> <p><b>n = 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF vs placebo 0.330 L (0.232 to 0.429)<br/> FF/VI vs placebo 0.331 L (0.231 to 0.43)<br/> FF/VI vs FF 0.001 L (‐0.096 to 0.097) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> <p>Change from baseline 4 to 10 hours post challenge</p> <p>At day 21</p> <p>Cross‐over trial ‐ 21 days</p> <p>LAR: absolute change from baseline in minimum FEV<sub>1</sub> between 4 and 10 hours following 1‐hour post‐treatment allergen challenge at day 21 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.216 L</b> <br/> <b>(‐0.343 to ‐0.088),</b> </p> <p><b>n = 26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.188 L</b> <br/> <b>(‐0.315 to ‐0.061),</b> </p> <p><b>n = 27</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.536 L</b> <br/> <b>(‐0.676 to ‐0.396),</b> </p> <p><b>n = 22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.731 L</b> <br/> <b>(‐0.878 to ‐0.584),</b> </p> <p><b>n = 20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) </p> <p>Change from baseline 4 to 10 hours post challenge</p> <p>At day 21</p> <p>LAR: absolute change from baseline in weighted mean FEV<sub>1</sub> between 4 and 10 hours following 1‐hour post‐treatment allergen challenge at day 21 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.018 L</b> <br/> <b>(‐0.089 to 0.125), n = 26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.018 L</b> <br/> <b>(‐0.089 to 0.124),</b> </p> <p><b>n = 27</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.298 L</b> <br/> <b>(‐0.415 to ‐0.181),</b> </p> <p><b>n = 22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.466 L</b> <br/> <b>(‐0.589 to ‐0.343),</b> </p> <p><b>n = 20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>Change from baseline trough FEV<sub>1</sub> </p> <p>At day 168</p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.281 L (0.0191),</b> </p> <p><b>n = 397</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.300 L (0.0193),</b> </p> <p><b>n = 389</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.019 L (‐0.073 to 0.034)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AM: morning; CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in one second; FF: fluticasone furoate; FP: fluticasone propionate; h: hour; LAR: late asthmatic response; MD: mean difference; PM: afternoon; SAL: salmeterol; SE: standard error; VI: vilanterol </p> </div> </div> <div class="table" id="CD010758-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Peak expiratory flow</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure of PEF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 100/25 mcg</b> </p> <p><b>Mean (SD, unless otherwise stated), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SD, unless otherwise stated), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE ), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Mean (SE, unless otherwise stated), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI, unless otherwise stated)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, AM</p> <p>Change from baseline in AM PEF Averaged over 12‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44.3 L/min (2.25)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19.1 L/min (2.25)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47.7 L/min (2.25)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.20 L/min (18.96 to 31.44), 100/25 vs 100 FF</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, PM</p> <p>Change from baseline in AM PEF Averaged over 12‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39.7 L/min (2.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15.5 L/min (2.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41.7 L/min (2.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.20 L/min (17.99 to 30.41), 100/25 vs 100 FF</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, PM</p> <p>Mean change from baseline in daily PM PEF averaged over 12‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26.4 L/min</b> </p> <p><b>(SE 2.35), n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14.1 L/min</b> </p> <p><b>(SE 2.34), n = 204</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐1.8 L/min (2.36),</b> </p> <p><b>n = 202</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.30 L/min (5.80 to 18.80), 28.20 L/min (21.67 to 34.73), 15.90 L/min (9.39 to 22.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, AM</p> <p>Only 1 (FF/VI) condition reported. Trial reported as conference abstract with limited information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline to day 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Least squares mean change calculated from baseline to day 15</p> <p>Least squares mean change in last 7 days, mean PEF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24.1 (2.46) AM</b> </p> <p><b>21.4 (2.58) PM</b> </p> <p><b>n = 172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐2.9 (2.44) AM</b> </p> <p><b>‐5.2 (2.51) PM</b> </p> <p><b>n = 187</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks' duration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39.1 L/min (3.01), n = 155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10.5 L/min (3.03), n = 154</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted treatment difference 28.5 L/min (20.1 to 36.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐treatment</p> <p>Pre‐treatment PEF at days 1 to 12</p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose:</b> </p> <p><b>510.4 L/min</b> <br/> <b>(95% CI 492.9 to 527.8), n = 24</b> </p> <p><b>PM dose:</b> </p> <p><b>535.3 L/min</b> <br/> <b>(95%CI 518.1 to 552.5), n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>466.3 L/min</b> <br/> <b>(95% CI 448.8 to 483.9), n = 24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 44.0 L/min (90% CI 31.2 to 56.9)</p> <p>PM vs placebo 69.0 L/min (90% CI 55.9 to 82.1)</p> <p>AM vs PM ‐25.0 L/min (90% CI ‐37.9 to ‐12.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐treatment</p> <p>Pre‐treatment PEF (PM) at days 1 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose:</b> </p> <p><b>517.6 L/min</b> <br/> <b>(95% CI 503.0 to 532.2), n = 24</b> </p> <p><b>PM dose:</b> </p> <p><b>521.4 L/min</b> <br/> <b>(95% CI 507.1 to 535.7), n = 26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>453.2 L/min</b> <br/> <b>(95% CI 438.5 to 467.9), n = 24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 64.4 L/min (90% CI 52.9 to 76.0)</p> <p>PM vs placebo 68.2 L/min (90% CI 56.5 to 79.8)</p> <p>AM vs PM ‐3.7 L/min (90% CI ‐15.2 to 7.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, AM</p> <p>4 weeks</p> <p>Mean change from baseline in daily trough (AM) PEF averaged over 24‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18.2 L/min (2.97),</b> </p> <p><b>n = 193</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>51.8L/min (2.94), n = 197</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18.8L/min (2.95), n = 195</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐33.60 L/min (‐41.79 to, ‐25.41), ‐0.60 L/min (‐8.80 to 7.60), 33.00 L/min (24.84 to 41.16) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, PM</p> <p>Mean change from baseline in daily trough (PM) PEF averaged over 24‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9.1 L/min (2.98),</b> </p> <p><b>n = 192</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39.8 L/min (2.93), n = 197</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13.6 L/min (2.96), n = 194</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐30.70 L/min (‐38.89 to ‐22.51), ‐4.50 L/min (‐12.73 to 3.73), 26.20 L/min (18.04 to 34.36) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AM: morning; CI: confidence interval; FF: fluticasone furoate; PEF: peak expiratory flow; PM: evening; SD: standard deviation; SE: standard error; VI: vilanterol </p> </div> </div> <p>Data contributed by <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> on FEV<sub>1</sub> (litres) indicated a significant difference in favour of VI and FF 100/25 mcg (MD 0.17, 95% CI 0.09 to 0.26; <a href="./references#CD010758-fig-0007" title="">Analysis 1.4</a>). A similar effect was reported for peak expiratory flow rate (PEFR) AM L/min (MD 28.20, 95% CI 21.67 to 34.73; <a href="./references#CD010758-fig-0008" title="">Analysis 1.5</a>) and PEFR AM L/min (MD 28.20, 95% CI 21.67 to 34.73; <a href="./references#CD010758-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD010758-sec-0072"> <h6 class="title">Asthma symptoms</h6> <p>See <a href="#CD010758-tbl-0009">Table 7</a>. </p> <div class="table" id="CD010758-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Asthma symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 100/25 mcg </b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL250/50 mcg twice‐daily</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥ 24 to 78 weeks' duration</p> <p>Responder analysis results: ORs for FF/VI vs FF at week 12 (1.49, 95% CI 1.20 to 1.84), week 36 (1.49, 95% CI 1.21 to 1.83) and at endpoint (1.50, 95% CI 1.23 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACQ7 mean difference and responder analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>Change from baseline in percentage of symptom‐free 24‐hour periods during 12‐week treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline % symptom‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27.2 (1.74)</b> </p> <p><b>n = 345</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19.4 (1.74)</b> </p> <p><b>n = 346</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29.0 (1.74)</b> </p> <p><b>n = 346</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>Change from baseline in % of symptom‐free 24‐hour periods during 12‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline % symptom‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32.5 (2.14),</b> </p> <p><b>n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20.4 (2.13),</b> </p> <p><b>n = 204</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14.6 (2.15), n = 202</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12.10 (6.18 to 18.02), 17.90 (11.95 to 23.85), 5.80 (‐0.13 to 11.73)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> </p> <p>Trial reported as conference abstract with limited information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>LS mean change in symptom‐free days during 2‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LS mean change in symptom‐free days (SE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7.3 (1.67) n = 172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.8 (1.64) n = 187</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>% of symptom‐free 24‐hour periods, weeks 1 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% symptom‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25.4 (2.74),</b> </p> <p><b>n = 155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20.6 (2.77),</b> </p> <p><b>n = 152</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.9 (‐2.8 to 12.5)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>Change from baseline in ACT scores at week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.9 (0.29), n = 164</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.8 (0.27), n = 183</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.9 (0.28), n = 169</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.90 (‐1.68 to ‐0.12), 0.00 (‐0.79 to 0.79), 0.90 (0.14 to 1.66)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) </p> <p>Change from baseline in ACT scores at week 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.2 (0.30), n = 147</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.5 (0.28), n = 170</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.7 (0.29), n = 162</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.30 (‐1.10 to 0.50), 0.50 (‐0.32 to 1.32), 0.80 (0.01 to 1.59)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>Change from baseline in ACT scores at day 168 and at</p> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.3 (0.16), n = 354</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.0 (0.16),</b> </p> <p><b>n = 348</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.2 (‐0.2 to 0.7)</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACT: asthma control test; CI: confidence interval; FF: fluticasone furoate; FP: fluticasone propionate; LS: least squares; MD: mean difference; NR: not reported; OR: odds ratio; SAL: salmeterol; SE: standard error; VI: vilanterol </p> </div> </div> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> reported a significant difference in favour of VI and FF 100/25 mcg with respect to change in asthma symptoms as measured by the Asthma Control Test (ACT) (MD 1.90, 95% CI 1.22 to 2.58; <a href="./references#CD010758-fig-0010" title="">Analysis 1.7</a>). </p> </section> </section> </section> <section id="CD010758-sec-0073"> <h4 class="title">VI and FF 100/25 mcg versus same dose of FF</h4> <section id="CD010758-sec-0074"> <h5 class="title">Primary outcomes</h5> <section id="CD010758-sec-0075"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> provided data on the change in quality of life (as measured by the AQLQ at 12 weeks) that indicated no statistically reliable difference between the two arms of this trial (MD 0.15, 95% CI ‐0.00 to 0.30; <a href="./references#CD010758-fig-0011" title="">Analysis 2.1</a>). </p> </section> <section id="CD010758-sec-0076"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p>Two studies provided data on exacerbations (<a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>). The difference between the two arms was not significant (odds ratio (OR) 1.38, 95% CI 0.86 to 2.22; <a href="./references#CD010758-fig-0012" title="">Analysis 2.2</a>). </p> </section> <section id="CD010758-sec-0077"> <h6 class="title">Serious adverse events</h6> <p>No serious adverse events were observed in either of the two arms in three of the five included studies (<a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) combined in <a href="./references#CD010758-fig-0013" title="">Analysis 2.3</a>. The difference between the two arms was not significant (OR 1.61, 95% CI 0.42 to 6.17). </p> </section> </section> <section id="CD010758-sec-0078"> <h5 class="title">Secondary outcomes</h5> <section id="CD010758-sec-0079"> <h6 class="title">Measures of lung function: FEV<sub>1</sub>, PEF </h6> <p>The trough FEV<sub>1</sub> at 12 weeks was significant in favour of VI and FF 100/25 mcg in a single study (<a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a>) (MD 0.08L, 95% CI 0.02 to 0.14; <a href="./references#CD010758-fig-0014" title="">Analysis 2.4</a>). </p> <p>Researchers reported a significant difference in favour of VI and FF 100/25 mcg for PEFR AM (change from baseline at 12 weeks) (MD 20.29, 95% CI 15.72 to 24.85; <a href="./references#CD010758-fig-0015" title="">Analysis 2.5</a>) and for PEFR PM (change from baseline at 12 weeks) (MD 18.52, 95% CI 14.03 to 23.01; <a href="./references#CD010758-fig-0016" title="">Analysis 2.6</a>). </p> <p>Data from a three‐period crossover study (<a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a>), which are reported in a format that cannot be aggregated in lung function analyses, also show a significant difference in favour of VI and FF 100/25 mcg of a similar magnitude for trough FEV<sub>1</sub> and PEFR AM and PM. </p> </section> <section id="CD010758-sec-0080"> <h6 class="title">Asthma symptoms</h6> <p>One study (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>) contributed data to this outcome, reporting no significant differences between the two arms with respect to change in asthma symptoms as measured by ACT (MD 0.60, 95% CI ‐0.04 to 1.24; <a href="./references#CD010758-fig-0017" title="">Analysis 2.7</a>). The minimal important difference on this scale is 0.5 unit. </p> </section> </section> </section> <section id="CD010758-sec-0081"> <h4 class="title">VI and FF 100/25 mcg versus same dose of VI</h4> <p>For this comparison, data on only one outcome were available for analysis: serious adverse events. Investigators observed no serious adverse events in either of the two arms of a single short‐term trial (<a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>; <a href="./references#CD010758-fig-0018" title="">Analysis 3.1</a>). </p> </section> <section id="CD010758-sec-0082"> <h4 class="title">VI and FF 100/25 mcg versus FP 500 mcg twice‐daily</h4> <section id="CD010758-sec-0083"> <h5 class="title">Primary outcomes</h5> <p>For this comparison, data were available for analysis on only two outcomes: exacerbations and serious adverse events. </p> <section id="CD010758-sec-0084"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p>Only one study of 52 weeks' duration contributed data to this analysis (<a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a>). Researchers reported no significant differences between VI and FF 100/25 mcg versus FP 500 mcg twice‐daily for this outcome (OR 0.49, 95% CI 0.10 to 2.47; <a href="./references#CD010758-fig-0019" title="">Analysis 4.1</a>). </p> </section> <section id="CD010758-sec-0085"> <h6 class="title">Serious adverse events</h6> <p>Only <a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> contributed data to this analysis. Investigators observed significantly fewer serious adverse events in the VI and FF 100/25 mcg arm (OR 0.20, 95% CI 0.05 to 0.80; <a href="./references#CD010758-fig-0020" title="">Analysis 4.2</a>). </p> </section> </section> </section> <section id="CD010758-sec-0086"> <h4 class="title">VI and FF 100/25 mcg versus FP/SAL 250/50 mcg twice‐daily</h4> <section id="CD010758-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD010758-sec-0088"> <h6 class="title">Health‐related quality of life</h6> <p>One study (<a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a>) of 24 weeks' duration considered change in quality of life (as measured by the AQLQ at 12 weeks). Investigators reported no significant differences between VI and FF 100/25 mcg versus FP/SAL 250/50 mcg twice‐daily (MD 0.09, 95% CI ‐0.03 to 0.21; <a href="./references#CD010758-fig-0021" title="">Analysis 5.1</a>). </p> </section> <section id="CD010758-sec-0089"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p>Researchers reported no significant differences between the two arms in terms of exacerbations (OR 0.50, 95% CI 0.05 to 5.52; <a href="./references#CD010758-fig-0022" title="">Analysis 5.2</a>). </p> </section> <section id="CD010758-sec-0090"> <h6 class="title">Serious adverse events</h6> <p>Study authors described no significant difference between the two arms for serious adverse events (OR 0.80, 95% CI 0.21 to 2.99; <a href="./references#CD010758-fig-0023" title="">Analysis 5.3</a>). </p> </section> </section> <section id="CD010758-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD010758-sec-0092"> <h6 class="title">Measures of lung function: FEV<sub>1</sub>, PEF </h6> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> reported no significant differences between the two arms for FEV<sub>1</sub> (MD ‐0.02, 95% CI ‐0.07 to 0.03; <a href="./references#CD010758-fig-0024" title="">Analysis 5.4</a>). </p> </section> <section id="CD010758-sec-0093"> <h6 class="title">Asthma symptoms</h6> <p>Study authors also described no significant differences between the two arms in terms of asthma symptoms (MD 0.24, 95% CI ‐0.20 to 0.68; <a href="./references#CD010758-fig-0025" title="">Analysis 5.5</a>). </p> </section> </section> </section> <section id="CD010758-sec-0094"> <h4 class="title">VI and FF 100/25 mcg versus FP/SAL 250/25 mcg twice‐daily</h4> <section id="CD010758-sec-0095"> <h5 class="title">Primary outcomes</h5> <p>For this comparison, data on only two outcomes were available for analysis: exacerbations and serious adverse events. </p> <section id="CD010758-sec-0096"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p>Only two studies provided data for this outcome: one short‐term trial (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>) and one of 52 weeks' duration (<a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a>). Investigators reported no significant differences between the two arms (OR 2.02, 95% CI 0.50 to 8.19; <a href="./references#CD010758-fig-0026" title="">Analysis 6.1</a>). </p> </section> <section id="CD010758-sec-0097"> <h6 class="title">Serious adverse events</h6> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> and <a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> also contributed data for serious adverse events, noting no significant differences between the two arms (OR 0.33, 95% CI 0.03 to 3.18; <a href="./references#CD010758-fig-0027" title="">Analysis 6.2</a>). </p> </section> </section> </section> <section id="CD010758-sec-0098"> <h4 class="title">VI and FF 200/25 mcg versus placebo</h4> <p>For this comparison, data on four outcomes were available for analysis: exacerbations, serious adverse events, FEV<sub>1</sub> and symptoms. </p> <section id="CD010758-sec-0099"> <h5 class="title">Primary outcomes</h5> <section id="CD010758-sec-0100"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p>Only one short‐term trial contributed data to this outcome (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>), indicating no exacerbations in either arm. </p> </section> <section id="CD010758-sec-0101"> <h6 class="title">Serious adverse events</h6> <p>Study authors also described no adverse events in either arm (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>). </p> </section> </section> <section id="CD010758-sec-0102"> <h5 class="title">Secondary outcomes</h5> <section id="CD010758-sec-0103"> <h6 class="title">Measures of lung function: FEV<sub>1</sub>, PEF </h6> <p>Only one study (24 weeks' duration; <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) provided data for this outcome (FEV<sub>1</sub> in litres), noting a significant advantage for VI and FF 200/25 mcg (MD 0.21, 95% CI 0.13 to 0.29; <a href="./references#CD010758-fig-0030" title="">Analysis 7.3</a>). </p> </section> <section id="CD010758-sec-0104"> <h6 class="title">Asthma symptoms</h6> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> described a similar significant advantage related to change in asthma symptoms for VI and FF 200/25 mcg (MD 0.90, 95% CI 0.12 to 1.68; <a href="./references#CD010758-fig-0031" title="">Analysis 7.4</a>). </p> </section> </section> </section> <section id="CD010758-sec-0105"> <h4 class="title">VI and FF 200/25 mcg versus FP/SAL 500/50 mcg</h4> <section id="CD010758-sec-0106"> <h5 class="title">Primary outcomes</h5> <p>The four week cross‐over trial addressing this comparison did not include the review's primary outcomes (<a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>). </p> </section> <section id="CD010758-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD010758-sec-0108"> <h6 class="title">Measures of lung function: FEV<sub>1</sub>, PEF </h6> <p><a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> reported an improvement in AM PEF in the VI/FF 200/25 mcg condition. However, investigators provided no information on this outcome in relation to the FP/SAL 500/50 mcg condition. </p> </section> <section id="CD010758-sec-0109"> <h6 class="title">Asthma symptoms</h6> <p>Only <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> looked at this comparison, noting no significant improvement on the ACT with either treatment. </p> </section> </section> </section> <section id="CD010758-sec-0110"> <h4 class="title">VI and FF 200/25 mcg versus FP 500 mcg</h4> <section id="CD010758-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD010758-sec-0112"> <h6 class="title">Health‐related quality of life</h6> <p>Two studies (<a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a>; <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) of 12 and 24 weeks' duration, respectively, looked at change in quality of life at 12 weeks (MD 0.05, 95% CI ‐0.08 to 0.17; <a href="./references#CD010758-fig-0032" title="">Analysis 8.1</a>) and at 24 weeks (MD 0.03, 95% CI ‐0.15 to 0.21; <a href="./references#CD010758-fig-0033" title="">Analysis 8.2</a>). Neither analysis indicated a significant difference between the two arms. </p> </section> <section id="CD010758-sec-0113"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> (52 weeks' duration) and <a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> provided data for this outcome, noting no significant differences between the two arms (OR 0.70, 95% CI 0.22 to 2.20; <a href="./references#CD010758-fig-0035" title="">Analysis 8.4</a>). </p> </section> <section id="CD010758-sec-0114"> <h6 class="title">Serious adverse events</h6> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013,</a><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> and <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> contributed data, indicating no significant differences between the two arms for this outcome (OR 0.61, 95% CI 0.25 to 1.49; <a href="./references#CD010758-fig-0036" title="">Analysis 8.5</a>). </p> </section> </section> <section id="CD010758-sec-0115"> <h5 class="title">Secondary outcomes</h5> <section id="CD010758-sec-0116"> <h6 class="title">Measures of lung function: FEV<sub>1</sub>, PEF </h6> <p>Only one study (<a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a>) provided data on PEF, reporting a significant advantage in favour of VI and FF 200/25 mcg (MD 28.60, 95% CI 20.23 to 36.97; <a href="./references#CD010758-fig-0037" title="">Analysis 8.6</a>). <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> provided additional data specifically for AM and PM PEFR. With respect to both the former (MD 33.00, 95% CI 24.84 to 41.16; <a href="./references#CD010758-fig-0038" title="">Analysis 8.7</a>) and the latter (MD 26.20, 95% CI 18.04 to 34.36; <a href="./references#CD010758-fig-0039" title="">Analysis 8.8</a>), a significant advantage favoured VI and FF 200/25 mcg. </p> </section> <section id="CD010758-sec-0117"> <h6 class="title">Asthma symptoms</h6> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> reported the proportion of symptom‐free days as a percentage for this comparison (MD 4.80, 95% CI ‐2.84 to 12.44; <a href="./references#CD010758-fig-0040" title="">Analysis 8.9</a>), revealing no significant differences for VI and FF 200/25 mcg versus FP 500 mcg in this analysis<b>.</b> However, for change in asthma symptoms, <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> provided an indication of significance in favour of VI and FF 200/25 mcg (MD 0.80, 95% CI 0.01 to 1.59; <a href="./references#CD010758-fig-0041" title="">Analysis 8.10</a>), based on the ACT, which has a minimal important difference of 0.5 unit. </p> </section> </section> </section> <section id="CD010758-sec-0118"> <h4 class="title">VI and FF 200/25 mcg versus same dose of FF</h4> <section id="CD010758-sec-0119"> <h5 class="title">Primary outcomes</h5> <section id="CD010758-sec-0120"> <h6 class="title">Health‐related quality of life</h6> <p>One study (<a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) considered change in health‐related quality of life at 12 weeks (MD 0.08, 95% CI ‐0.08 to 0.24; <a href="./references#CD010758-fig-0042" title="">Analysis 9.1</a>) and at 24 weeks (MD 0.05, 95% CI ‐0.14 to 0.24; <a href="./references#CD010758-fig-0043" title="">Analysis 9.2</a>). Both cases reported no significant differences between VI and FF 200/25 mcg versus the same dose of FF for this outcome. </p> </section> <section id="CD010758-sec-0121"> <h6 class="title">Severe asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroid </h6> <p>No data were available for inclusion in our analyses for this outcome.</p> </section> <section id="CD010758-sec-0122"> <h6 class="title">Serious adverse events</h6> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> provided data showing no significant differences between VI and FF 200/25 mcg versus the same dose of FF for this outcome (OR 6.06, 95% CI 0.72 to 50.84; <a href="./references#CD010758-fig-0044" title="">Analysis 9.3</a>). </p> </section> </section> <section id="CD010758-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD010758-sec-0124"> <h6 class="title">Measures of lung function: FEV<sub>1</sub>, PEF </h6> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> contributed data showing a significant advantage in favour of VI and FF 200/25 mcg for FEV<sub>1</sub> (litres) (MD 0.19, 95% CI 0.10 to 0.28; <a href="./references#CD010758-fig-0045" title="">Analysis 9.4</a>), PEFR AM (MD 33.60, 95% CI 25.41 to 41.79; <a href="./references#CD010758-fig-0046" title="">Analysis 9.5</a>) and PEFR PM (MD 30.70, 95% CI 22.51 to 38.89; <a href="./references#CD010758-fig-0047" title="">Analysis 9.6</a>). </p> </section> <section id="CD010758-sec-0125"> <h6 class="title">Asthma symptoms</h6> <p>Data from <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> revealed no significant differences between VI and FF 200/25 mcg versus the same dose of FF for this outcome (MD 0.30, 95% CI ‐0.50 to 1.10; <a href="./references#CD010758-fig-0048" title="">Analysis 9.7</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010758-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010758-sec-0126"></div> <section id="CD010758-sec-0127"> <h3 class="title" id="CD010758-sec-0127">Summary of main results</h3> <p>We found very few opportunities to combine results from the 14 included studies into meta‐analyses. We tabulated the data for our pre‐specified primary outcomes: health‐related quality of life (<a href="#CD010758-tbl-0004">Table 2</a>), exacerbations (<a href="#CD010758-tbl-0005">Table 3</a>) and serious adverse events (<a href="#CD010758-tbl-0006">Table 4</a>). We included nine comparisons in this review, six for which the dose of vilanterol (VI) and fluticasone furoate (FF) was 100/25 mcg (VI and FF 100/25 mcg vs placebo; VI and FF 100/25 mcg vs same dose of FF; VI and FF 100/25 mcg vs same dose of VI; VI and FF 100/25 mcg vs fluticasone propionate (FP) 500 mcg twice‐daily; VI and FF 100/25 mcg vs FP/salmeterol (SAL) 250/50 mcg twice‐daily; VI and FF 100/25 mcg vs FP/SAL 250/25 mcg twice‐daily) and three for which the dose of VI and FF was 200/25 mcg (VI and FF 200/25 mcg vs placebo; VI and FF 200/25 mcg vs FP 500 mcg; VI and FF 200/25 mcg vs same dose of FF). In this review, we focused on our pre‐specified primary outcomes: health‐related quality of life, severe asthma exacerbation as defined by hospital admission, treatment with a course of oral corticosteroid and serious adverse events. </p> <p>In the comparison between VI and FF 100/25 mcg versus placebo, only one study (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>) provided data on health‐related quality of life, showing a significant difference in favour of VI and FF 100/25 mcg (mean difference (MD) 0.30, 95% confidence interval (CI) 0.14 to 0.46; <a href="./references#CD010758-fig-0004" title="">Analysis 1.1</a>) when using the Asthma Quality of Life Questionnaire (AQLQ) with a minimally important difference of 0.5 unit. The two studies contributing data (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) reported no exacerbations in the VI and FF 100/25 mcg or placebo arms, and the five aggregated studies (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) described no serious adverse events in the VI and FF 100/25 mcg or placebo arms. When viewed together, these data provide some evidence of benefit; however, in light of the small number of studies contributing to this impression and their mostly very short duration, it should be noted that this does not constitute strong evidence for efficacy nor for safety. </p> <p>The second comparison (VI and FF 100/25 mcg vs same dose of FF) indicated no statistically reliable difference for health‐related quality of life between the two arms of the single contributing study (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; MD 0.15, 95% CI ‐0.00 to 0.30). Only two studies provided data on exacerbations (<a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>), noting that the difference between the two arms was not significant (odds ratio (OR) 1.38, 95% CI 0.86 to 2.22). Researchers noted no serious adverse events in either of the two arms in three of the five included studies (<a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>), and no significant differences between the two conditions for this outcome (OR 1.61, 95% CI 0.42 to 6.17). The small number of studies contributing data to this comparison precludes opportunities for drawing robust conclusions for this comparison as well. </p> <p>In terms of our comparison between VI and FF 100/25 mcg versus same dose of VI, data were available for analysis on only one of our pre‐specified primary outcomes: serious adverse events; no serious adverse events were observed in either of the two arms of the aggregated study (<a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>). </p> <p>For the comparison between VI and FF 100/25 mcg versus FP 500 mcg twice‐daily, data were available for analysis for only two outcomes: exacerbations and serious adverse events. Only one study contributed data with respect to the former (<a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a>), reporting no significant differences between the two interventions (OR 0.49, 95% CI 0.10 to 2.4). With regard to serious adverse events only, <a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> contributed data, revealing significantly fewer serious adverse events in the VI and FF 100/25 mcg arm (OR 0.20, 95% CI 0.05 to 0.80). Again, the small number of contributing studies precludes the opportunity for reaching any robust conclusions. </p> <p>Researchers also compared VI and FF 100/25 mcg versus FP/SAL 250/50 mcg twice‐daily. In terms of health‐related quality of life, which was considered by only one study (<a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a>), data show no significant differences between the two arms (MD 0.09, 95% CI ‐0.03 to 0.21) and no significant differences between the two arms in terms of exacerbations (OR 0.50, 95% CI 0.05 to 5.52), or between the two arms for serious adverse events (OR 0.80, 95% CI 0.21 to 2.99). </p> <p>Finally, in terms of comparisons including VI and FF at 100/25 mcg, we considered VI and FF 100/25 mcg versus FP/SAL 250/25 mcg twice‐daily. Data on only two outcomes were available for analysis: exacerbations and serious adverse events. </p> <p>For exacerbations, only two studies (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a>) provided data, revealing no significant differences between the two arms (OR 2.02, 95% CI 0.50 to 8.19). These studies also contributed data on serious adverse events, showing no significant differences between the two arms (OR 0.33, 95% CI 0.03 to 3.18). </p> <p>In summary, with respect to VI and FF at 100/25 mcg, it is not possible to draw strong conclusions in relation to our pre‐specified primary outcomes. </p> <p>Investigators also considered VI and FF at the higher dose of 200/25 mcg. For the comparison VI and FF 200/25 mcg versus placebo, data on only two of our primary outcomes were available for analysis: exacerbations and serious adverse events. Only one study contributed data on these two outcomes (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>), noting no exacerbations in either arm and no adverse events in either arm. </p> <p>Study authors also compared VI and FF 200/25 mcg versus FP 500 mcg. Two studies (<a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a>; <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) looked at change in quality of life at 12 weeks (MD 0.05, 95% CI ‐0.08 to 0.17) and at 24 weeks (MD 0.03, 95% CI ‐0.15 to 0.21; <a href="./references#CD010758-fig-0033" title="">Analysis 8.2</a>); neither analysis indicated a significant difference between the two arms. <a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> and <a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> provided data on exacerbations, showing no significant differences between the two arms (OR 0.70, 95% CI 0.22 to 2.20). Three studies (<a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a>; <a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a>; <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) contributed data on serious adverse events, showing no significant differences between the two arms for this outcome (OR 0.61, 95% CI 0.25 to 1.49). </p> <p>In addition, study authors described the comparison between VI and FF 200/25 mcg versus same dose of FF. <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> considered change in health‐related quality of life at 12 weeks (MD 0.08, 95% CI ‐0.08 to 0.24) and at 24 weeks (MD 0.05, 95% CI ‐0.14 to 0.24), with neither analysis indicating a significant difference between the two interventions. No data were available for inclusion in our analyses on exacerbations. With regard to serious adverse events, <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> provided data, revealing no significant differences between the two interventions for this outcome (OR 6.06, 95% CI 0.72 to 50.84). </p> <p>In summary, the evidence gathered in relation to our primary outcomes for VI and FF at 100/25 mcg and at 200/25 mcg is too inconclusive to provide the basis of robust conclusions. </p> </section> <section id="CD010758-sec-0128"> <h3 class="title" id="CD010758-sec-0128">Overall completeness and applicability of evidence</h3> <p>At the present time, inhaled corticosteroid (ICS) and long‐acting beta<sub>2</sub>‐agonist (LABA) combination inhalers are recommended at step 3 of the British Thoracic Society (BTS) guidelines for asthma management in children and adults. This means that patients taking a low dose of ICS should have their treatment 'stepped up' to include a LABA in addition to continued ICS only if their asthma is not well controlled. This treatment pathway has a clear evidence base. The question is whether the combination of VI and FF could be also be used at this stage. Owing to the wide range of comparisons and the short duration of most trials, applicability of the evidence is very limited. </p> <p>From the limited number of available studies, some evidence has supported the use of VI/FF, particularly with regard to forced expiratory volume in one second (FEV<sub>1</sub>) and peak expiratory flow (PEF) (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>; <a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>); however, additional studies are required to support its role. Research has suggested that the combination may improve health‐related quality of life compared with placebo (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>), but longer‐term placebo‐controlled studies are required to support this finding. The evidence reviewed reveals no significant short‐term increase in asthma exacerbations (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) nor in serious adverse events (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) in the VI/FF group. Evidence is presently insufficient for comparison of VI/FF versus alternative twice‐daily combination therapy inhalers. </p> <p>Studies have excluded participants with an episode of life‐threatening asthma, so potentially, these trials may have excluded a group of participants with more severe disease. </p> <p>Most studies included adult and adolescent participants, and only one study enrolled only paediatric participants (<a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a>). Confirmation of benefit for paediatric patients is important ‐ particularly as a once‐daily dosing regimen may improve adherence in the paediatric population. Large variability in study duration and in the severity of asthma heterogeneity makes it difficult to examine safety and side effects. </p> </section> <section id="CD010758-sec-0129"> <h3 class="title" id="CD010758-sec-0129">Quality of the evidence</h3> <p>In our judgement, 12 of the 14 studies had low risk of selection bias; in <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> and <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>, the risk was considered to be unclear. We also judged performance bias and detection bias based on blinding processes to be low in 12 of the 14 studies; in <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> and <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>, we judged this risk to be unclear. We evaluated attrition bias to be similarly low in 12 of the 14 studies; we judged the risk to be unclear in <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> and <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a>. In our judgement, risk of reporting bias was low in 13 studies, and we judged <a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> as having unclear risk in this respect. In summary, we believe the quality of the evidence with respect to risk of bias was generally uniform across the various categories assessed (<a href="#CD010758-fig-0003">Figure 3</a>). </p> <p>The small number of included studies precluded formal assessment of publication bias using funnel plots. However, we designed our search strategy, which extended to conference abstracts and ongoing studies, with the goal of identifying unpublished studies. </p> </section> <section id="CD010758-sec-0130"> <h3 class="title" id="CD010758-sec-0130">Potential biases in the review process</h3> <p>Potential for publication bias can be seen in this review in that unpublished trials may not have been included. These studies may have had positive or negative outcomes that would have affected described treatment benefits. We undertook a thorough and systematic search of databases, and to the best of our knowledge, we assessed all relevant studies for inclusion in this review. Two review authors independently evaluated all studies that met the inclusion criteria to reduce potential selection bias. Assessment of each study was consistent in relation to the inclusion criteria. </p> </section> <section id="CD010758-sec-0131"> <h3 class="title" id="CD010758-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>We found the main body of evidence for use of VI and FF in the randomised controlled trials (RCTs) represented in this review. We are not aware of any other systematic review on this topic. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010758-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010758-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010758-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010758-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FF/VI 100/25 versus placebo, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk)." data-id="CD010758-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 FF/VI 100/25 versus placebo, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FF/VI 100/25 versus placebo, Outcome 2 Exacerbations." data-id="CD010758-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 FF/VI 100/25 versus placebo, Outcome 2 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FF/VI 100/25 versus placebo, Outcome 3 Serious adverse events." data-id="CD010758-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 FF/VI 100/25 versus placebo, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FF/VI 100/25 versus placebo, Outcome 4 FEV1 Litres." data-id="CD010758-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 FF/VI 100/25 versus placebo, Outcome 4 FEV<sub>1</sub> Litres. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FF/VI 100/25 versus placebo, Outcome 5 PEFR AM L/min (change from baseline at 12 wk)." data-id="CD010758-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 FF/VI 100/25 versus placebo, Outcome 5 PEFR AM L/min (change from baseline at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FF/VI 100/25 versus placebo, Outcome 6 PEFR PM L/min (change from baseline at 12 wk)." data-id="CD010758-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 FF/VI 100/25 versus placebo, Outcome 6 PEFR PM L/min (change from baseline at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FF/VI 100/25 versus placebo, Outcome 7 Change in asthma symptoms (measured by ACT)." data-id="CD010758-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 FF/VI 100/25 versus placebo, Outcome 7 Change in asthma symptoms (measured by ACT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk)." data-id="CD010758-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 2 Exacerbations." data-id="CD010758-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 2 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 3 Serious adverse events." data-id="CD010758-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 4 Trough FEV1 (L)." data-id="CD010758-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 4 Trough FEV<sub>1</sub> (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 5 PEFR AM (change from baseline at 12 wk)." data-id="CD010758-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 5 PEFR AM (change from baseline at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 6 PEFR PM (change from baseline at 12 wk)." data-id="CD010758-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 6 PEFR PM (change from baseline at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 7 Change in asthma symptoms (measured by ACT)." data-id="CD010758-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 7 Change in asthma symptoms (measured by ACT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FF/VI 100/25 versus same dose VI, Outcome 1 Serious adverse events." data-id="CD010758-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 FF/VI 100/25 versus same dose VI, Outcome 1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FF/VI 100/25 versus FP 500 µg, Outcome 1 Exacerbations." data-id="CD010758-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 FF/VI 100/25 versus FP 500 µg, Outcome 1 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FF/VI 100/25 versus FP 500 µg, Outcome 2 Serious adverse events." data-id="CD010758-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 FF/VI 100/25 versus FP 500 µg, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 1 Change in quality of life (measured by AQLQ at 24 wk)." data-id="CD010758-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 1 Change in quality of life (measured by AQLQ at 24 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 2 Exacerbations." data-id="CD010758-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 2 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 3 Serious adverse events." data-id="CD010758-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 4 FEV1." data-id="CD010758-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 4 FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 5 Change in asthma symptoms (measured by ACT)." data-id="CD010758-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 5 Change in asthma symptoms (measured by ACT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 FF/VI 100/25 µg versus FF/VI 200/25 µg, Outcome 1 Exacerbations." data-id="CD010758-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 FF/VI 100/25 µg versus FF/VI 200/25 µg, Outcome 1 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 FF/VI 100/25 µg versus FF/VI 200/25 µg, Outcome 2 Serious adverse events." data-id="CD010758-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 FF/VI 100/25 µg versus FF/VI 200/25 µg, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 FF/VI 200/25 versus placebo, Outcome 1 Exacerbations." data-id="CD010758-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 FF/VI 200/25 versus placebo, Outcome 1 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 FF/VI 200/25 versus placebo, Outcome 2 Serious adverse events." data-id="CD010758-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 FF/VI 200/25 versus placebo, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 FF/VI 200/25 versus placebo, Outcome 3 FEV1 Litres." data-id="CD010758-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 FF/VI 200/25 versus placebo, Outcome 3 FEV<sub>1</sub> Litres. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 FF/VI 200/25 versus placebo, Outcome 4 Change in asthma symptoms (measured by ACT)." data-id="CD010758-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 FF/VI 200/25 versus placebo, Outcome 4 Change in asthma symptoms (measured by ACT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk)." data-id="CD010758-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 2 Change in quality of life (measured by AQLQ at 24 wk)." data-id="CD010758-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 2 Change in quality of life (measured by AQLQ at 24 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 3 OLD***Health‐related quality of life." data-id="CD010758-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 3 OLD***Health‐related quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 4 Exacerbations." data-id="CD010758-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 4 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 5 Serious adverse events." data-id="CD010758-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 5 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 6 PEFR." data-id="CD010758-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 6 PEFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 7 PEFR AM." data-id="CD010758-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 7 PEFR AM.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 8 PEFR PM." data-id="CD010758-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 8 PEFR PM.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 9 % symptom‐free days." data-id="CD010758-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 9 % symptom‐free days.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 10 Change in asthma symptoms (measured by ACT)." data-id="CD010758-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 10 Change in asthma symptoms (measured by ACT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk)." data-id="CD010758-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 1 Change in quality of life (measured by AQLQ at 12 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 2 Change in quality of life (measured by AQLQ at 24 wk)." data-id="CD010758-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 2 Change in quality of life (measured by AQLQ at 24 wk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 3 Serious adverse events." data-id="CD010758-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 4 FEV1 Litres." data-id="CD010758-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 4 FEV<sub>1</sub> Litres. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 5 PEFR AM." data-id="CD010758-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 5 PEFR AM.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 6 PEFR PM." data-id="CD010758-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 6 PEFR PM.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010758-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/urn:x-wiley:14651858:media:CD010758:CD010758-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_t/tCD010758-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 7 Change in asthma symptoms (measured by ACT)." data-id="CD010758-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 7 Change in asthma symptoms (measured by ACT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/media/CDSR/CD010758/image_n/nCD010758-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010758-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vilanterol and fluticasone furoate compared with placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>VI and FF compared with placebo for asthma</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with asthma </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> VI and FF </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>VI and FF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.61<br/> (SE 0.061),<br/> n = 149 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.91 (SE 0.055),</p> <p>n = 180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 0.30, 95% CI 0.14 to 0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> (N = 609 participants, 515 completed study) compared VI/FF 100/25 mcg vs placebo in respect of health‐related quality of life and indicated a significant advantage for VI/FF 100/25 mcg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthma exacerbation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 studies (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> and <a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>a) compared VI/FF 100/25 mcg vs placebo in respect of exacerbations; both studies reported no exacerbations in either treatment arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Five trials (<a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a>; <a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>; <a href="./references#CD010758-bbs2-0022" title='KempsfordR , AllenA , KellyK , SagguP , CrimC . A repeat dose, double‐blind, placebo‐controlled "Thorough QT/QTc Study" to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered in combination [Abstract]. American Thoracic Society International Conference; 2012 May 18‐23; San Francisco. 2012; Vol. 185, issue Meeting Abstracts:A2841. '>Kempsford 2012a</a>; <a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>; <a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) made this same comparison in relation to serious adverse events; all 5 reported no serious adverse events in VI/FF100/25 mcg or placebo arms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.196 L<br/> (SE 0.0310), </p> <p>n = 193</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.368 L</p> <p>(SE 0.0304),</p> <p>n = 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 0.17 L, 95% CI 0.09 to 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant difference in favour of VI/FF 100/25 mcg vs placebo with respect to mean change in trough FEV<sub>1</sub> (pre‐bronchodilator and pre‐dose) from baseline to week 12 in 1 trial (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>) (N = 609 participants, 515 completed study) (MD 0.17 L, 95% CI 0.09 to 0.26), and a similar effect was found in a small cross‐over trial (<a href="./references#CD010758-bbs2-0022" title='KempsfordR , AllenA , KellyK , SagguP , CrimC . A repeat dose, double‐blind, placebo‐controlled "Thorough QT/QTc Study" to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered in combination [Abstract]. American Thoracic Society International Conference; 2012 May 18‐23; San Francisco. 2012; Vol. 185, issue Meeting Abstracts:A2841. '>Kempsford 2012a</a>) over a 2‐week period in the morning (MD 0.377 L, 90% CI 0.293 to 0.462) and in the evening (MD 0.422 L, 90% CI 0.337 to 0.507) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peak expiratory flow</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐0.4 L/min (SE 2.42),<br/> n = 203 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32.9 L/min</p> <p>(SE 2.42),</p> <p>n = 201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 33.30 L/min,</p> <p>95% CI 26.59 to 40.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> (N = 609 participants, 515 completed study) compared VI/FF 100/25 mcg vs placebo as mean change from baseline in daily morning (AM) PEF averaged over 12‐week treatment period; researchers noted a significant difference in favour of VI/FF 100/25 mcg (MD 33.30 L/min, 95% CI 26.59 to 40.01). The same trial showed a similar advantage in favour of VI/FF 100/25 mcg vs placebo in the evening over this period (28.20 L/min, 95% CI 21.67 to 34.73). A small cross‐over trial (<a href="./references#CD010758-bbs2-0022" title='KempsfordR , AllenA , KellyK , SagguP , CrimC . A repeat dose, double‐blind, placebo‐controlled "Thorough QT/QTc Study" to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered in combination [Abstract]. American Thoracic Society International Conference; 2012 May 18‐23; San Francisco. 2012; Vol. 185, issue Meeting Abstracts:A2841. '>Kempsford 2012a</a>) produced a similar effect in favour of VI/FF 100/25 mcg vs placebo over a 2‐week period in the morning (MD 44.0 L/min, 90% CI 31.2 to 56.9) and in the evening (MD 69.0 L/min, 90% CI 55.9 to 82.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthma symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14.6</p> <p>(SE 2.15),</p> <p>n = 202</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32.5 (SE 2.14),</p> <p>n = 201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 17.90, 95% CI 11.95 to 23.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 trial (<a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a>) (N = 609 participants, 515 completed study) made VI/FF vs placebo comparison with respect to asthma symptoms, indicating a clear advantage for VI/FF 100/25 mcg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Several trials reported a range of adverse events for which overall aggregation was not possible. These are tabulated in <a href="./full#CD010758-tbl-0002">Table 8</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> AM: morning; CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in one second; FF: fluticasone furoate; GRADE: Grades of Recommendation, Assessment, Development and Evaluation Working Group; MD: mean difference; OR: odds ratio; PEF: peak expiratory flow; PM: afternoon; RR: risk ratio; SE: standard error; VI: vilanterol </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Point deducted to reflect that these data were derived from only one trial </p> <p><sup>b</sup>Investigators reported no events in either arm of these trials </p> <p><sup>c</sup>Point deducted to reflect that data contributing to the main result (MD 0.17 L, 95% CI 0.09 to 0.26) were obtained from only one trial </p> <p><sup>d</sup>Point deducted, as we were unable to combine data on this outcome; results are presented in a separate table </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vilanterol and fluticasone furoate compared with placebo for asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0002"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>200/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VI 25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL</b> </p> <p><b>250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prednisolone </b> </p> <p><b>10 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> </p> <p>6 weeks' duration. On‐treatment AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23/56 (41.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21/56 (38.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5/15 (33.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16/58 (28.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥24 to 78 weeks' duration. On‐treatment AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>636/1009 (63.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>652/1010 (65.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54/346 (15.61%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>67/347 (19.31%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>52/346 (15.03%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29/201 (14.43%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20/205 (9.76%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22/203 (10.84%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> <p>52 weeks' duration. On‐treatment AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>139/201 (69.15%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>134/202 (66.34%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73/100 (73.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>Cross‐over trial. 3 of 7 treatments (2 weeks) separated by 12 to 14‐day washout periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43/172 (25%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25/187 (13%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration. Any AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>40/155 (26.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41/154 (27.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period between periods </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11/24 (45.83%) AM</b> </p> <p><b>12/25 (48.00%) PM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8/23 (34.78%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66/194 (34.02%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62/197 (31.47%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73/195 (37.44%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a> </p> <p>Cross‐over trial. 11 weeks (for a single period)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4/25 (16.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/25 (4.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a> </p> <p>Cross‐over trial. 28 days for each period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11/51 (21.57%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18/51 (35.29%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15/51 (29.41%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> <p>Cross‐over trial. 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20/27 (74.07%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19/27 (70.37%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22/26 (84.62%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19/27 (70.37%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>110/403 (27.30%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106/403 (26.30%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Fractions shown in the table indicate the proportions of people who suffered one or more adverse events of any cause in each treatment arm </p> <p>AE: adverse event; F: fluticasone furoate; FP: fluticasone propionate; SAL: salmeterol; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (weeks) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity at baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility &gt; 12%</p> <p> </p> <p>FEV<sub>1</sub> &gt; 50% of predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Comply with treatment</p> <p> </p> <p>Clinical diagnosis of asthma for ≥ 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cortisol urinary excretion, serum AUC and trough</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 to 78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility &gt; 12%</p> <p> </p> <p>FEV<sub>1</sub> &gt; 50% to 90% of predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Using ICS</p> <p> </p> <p>History of ≥ 1 exacerbation requiring hospitalisation or steroids in the past year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility &gt; 12%</p> <p>FEV<sub>1</sub> 50% to 80% of predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS for &gt; 12 weeks before study</p> <p> </p> <p>&gt; 12 years of age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, not clear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 90% of predicted normal </p> <p>Reversibility FEV<sub>1</sub> ≥ 12% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS for 12 weeks before study</p> <p> </p> <p>&gt; 12 years of age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 90% of predicted normal </p> <p>Reversibility FEV<sub>1</sub> ≥ 12% </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Clinical diagnosis of asthma</p> <p> </p> <p>ICS at high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACT suggesting poor control and FEV<sub>1</sub> mean  70% (SD 11%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma ≥ 20 years of age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No, conference abstract only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 80% of predicted </p> <p>Demonstrated reversibility by ≥ 12%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for regular controller therapy for minimum of 8 weeks</p> <p>Stable dose of ICS for ≥ 4 weeks</p> <p>≥ 18 years of age</p> <p>Diagnosis of asthma for ≥ 6 months</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility of disease: demonstrated ≥ 12% and</p> <p>FEV<sub>1</sub> 40% to 90% </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS, with or without LABA, for ≥ 12 weeks</p> <p>Clinical diagnosis of asthma for 12 weeks</p> <p> </p> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> ≥ 60% of predicted. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 and 70 years of age inclusive</p> <p>Using an ICS, with or without a SABA, for ≥ 12 weeks before screening</p> <p>Participants who are current non‐smokers, who have not used inhaled tobacco products in the 12‐month period preceding screening visit </p> <p>Body weight ≥ 50 kg and BMI within the range 19.0 to 29.9 kg/m<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, details not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> 40% to 90% of predicted </p> <p>Reversibility FEV<sub>1</sub> ≥ 12% </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Current asthma therapy that includes an ICS for ≥ 12 weeks before first visit</p> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cortisol, ECG, mouth swabs, various blood parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate (GINA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stable asthma therapy (FP, total daily dose ≤ 400 mcg or equivalent) and SABA inhaler for ≥ 4 weeks before screening </p> <p>5 to 12 years of age</p> <p>Clinical diagnosis of asthma 6 months before</p> <p>Controlled asthma (Childhood ACT &gt; 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> &gt; 70% of predicted at screening </p> <p> </p> <p>Methacholine challenge PC20 &lt; 8 mg/mL at screening</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> <p>Stable asthma therapy (FP, total daily dose ≤ 400 mcg or equivalent) and SABA inhaler for ≥ 4 weeks before screening </p> <p>BMI within the range 18.5 to 35.0 kg/m<sup>2</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 with 3 weeks' washout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> &gt; 70% of predicted at screening </p> <p> </p> <p>Methacholine challenge PC20 &lt; 8 mg/mL at screening</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stable asthma therapy (FP, total daily dose ≤ 400 mcg or equivalent) and SABA inhaler for ≥ 4 weeks before screening </p> <p>BMI within the range 18.5 to 35.0 kg/m<sup>2</sup> </p> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reversibility ≥ 12% and 200 mL within 10 to 40 minutes following 2 to 4 inhalations of albuterol </p> <p>FEV<sub>1</sub> 40% to 85% predicted normal </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Currently using ICS therapy</p> <p>Clinical diagnosis of asthma</p> <p>Adults  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ACT: Asthma Control Test</p> <p>AUC: area under the curve</p> <p>BMI: body mass index</p> <p>ECG: electrocardiogram</p> <p>FEV<sub>1</sub>: forced expiratory volume in one second </p> <p>FP: fluticasone propionate</p> <p>GINA: Global Initiative for Asthma</p> <p>ICS: inhaled corticosteroid</p> <p>LABA: long‐acting beta<sub>2</sub>‐agonist </p> <p>PC20: provocative concentration of methacholine estimated to result in a 20% reduction in FEV<sub>1</sub> </p> <p>SABA: short‐acting beta<sub>2</sub>‐agonist </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Health‐related quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>score (change from baseline)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 100/25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL 250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>AQLQ change from baseline at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.91 (0.055),</b> </p> <p><b>n = 180</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.76 (0.055),</b> </p> <p><b>n = 184</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61 (0.061),</b> </p> <p><b>n = 149</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.15 (0.00 to 0.30), 0.30 (0.14 to 0.46), 0.15 (‐0.01 to 0.31)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>AQLQ change from baseline at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.80 (0.069),</b> </p> <p><b>n = 140</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.69 (0.074),</b> </p> <p><b>n = 123</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12 (‐0.08 to 0.32)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>AQLQ change from baseline at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.061),</b> </p> <p><b>n = 154</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.056),</b> </p> <p><b>n = 180</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.059),</b> </p> <p><b>n = 163</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.08 (‐0.24 to 0.08), ‐0.08 (‐0.25 to 0.09), 0.00 (‐0.16 to 0.16)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>AQLQ change from baseline at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.88 (0.071),</b> </p> <p><b>n = 140</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.93 (0.065),</b> </p> <p><b>n = 167</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.90 (0.068),</b> </p> <p><b>n = 156</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.05 (‐0.24 to 0.14), ‐0.02 (‐0.21 to 0.17), 0.03 (‐0.15 to 0.21)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>AQLQ change from baseline at 168 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46 (0.043),</b> </p> <p><b>n = 342</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.37 (0.043), n = 335</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09 (‐0.03 to 0.21)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>EQ‐5D change from baseline at 168 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.5 (0.60),</b> </p> <p><b>n = 343</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.1 (0.60), n = 349</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.4 (‐0.3 to 3.0)</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AQLQ: asthma quality of life questionnaire; CI: confidence interval; EQ‐5D: EuroQuality of Life‐5D questionnaire; FF: fluticasone furoate; FP: fluticasone propionate; MD: mean difference; SAL: salmeterol; SE: standard error; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Health‐related quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Asthma exacerbation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF </b> </p> <p><b>200 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>200/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL</b> </p> <p><b>250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP </b> </p> <p><b>500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prednisolone </b> </p> <p><b>10 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a><sup>a</sup> </p> <p>6 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/15 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/58 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥ 24 to 78 weeks' duration</p> <p>Time to first severe exacerbation (HR 0.80, 95% CI 0.64 to 0.99). Annualised rate of severe exacerbation 25% reduction (95% CI 5% to 40%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>154/1009 (15.26%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>186/1010 (18.42%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> <p>52 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/201 (1.49%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6/202 (2.97%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/100 (3.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/155 (0.65%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/154 (1.95%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period between periods </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/24 (0.00%) AM</b> </p> <p><b>0/25 (0.00%) PM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/23 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a><sup>b</sup> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/403 (0.25%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2/403 (0.50%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>One participant in the FF/VI 100/25 mcg group experienced a severe asthma exacerbation concurrent with sinusitis and was withdrawn owing to lack of efficacy. The participant did not require hospitalisation, and the event, which was not classified as an AE, resolved following treatment with prednisone </p> <p><sup>b</sup>The incidence of asthma exacerbations was low, and no difference was noted between groups (3% vs 2% on FP/SAL vs FF/VI, respectively (on‐treatment events)). Eight (2%) participants in the FF/VI group and seven (2%) in the FP/SAL group withdrew because of exacerbation. One patient in the FF/VI group and two in the FP/SAL group were hospitalised because of exacerbation </p> <p>AM: morning; CI: confidence interval; FF: fluticasone furoate; FP: fluticasone propionate; HR: hazard ratio; PM: afternoon; SAL: salmeterol; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Asthma exacerbation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF </b> </p> <p><b>200 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>200/25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VI 25 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL</b> </p> <p><b>250/50 mcg twice‐daily</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prednisolone </b> </p> <p><b>10 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0001" title="AllenA , SchenkenbergerI , TrivediR , ColeJ , HicksW , GulN , et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study. Clinical Respiratory Journal2013;7(4):397‐406. NCT01086410 . Safety study of the effects of inhaled fluticasone furoate/GW642444 on the hypothalamic‐pituitary‐adrenal (HPA) axis. https://clinicaltrials.gov/ct2/show/NCT01086410 (accessed 17/6/15). ">Allen 2013</a> </p> <p>6 weeks' duration. Post‐treatment period SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/56 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/15 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/58 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥ 24 to 78 weeks' duration. On‐treatment SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41/1009 (4.06%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29/1010 (2.87%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4/346 (1.16%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/347 (0.86%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/346 (0.29%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/201 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/205 (0.49%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/203 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0005" title="BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long‐acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2092]. BusseWW , O'ByrnePM , BleeckerER , LotvallJ , WoodcockA , AndersenL , et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients &gt;=12 years old with asthma: a randomised trial. Thorax2013;68(6):513‐20. NCT01018186 . Fluticasone furoate/GW642444 inhalation powder long‐term safety study. http://clinical trials.gov/show/NCT01018186 (accessed 17/6/15). ">Busse 2013</a> </p> <p>52 weeks' duration. On‐treatment SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3/201 (1.49%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/202 (0.50%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7/100 (7.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>Cross‐over trial. Three of 7 treatments (2 weeks) separated by 12 to 14‐day washout periods </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/172</b> </p> <p><b>(0.006%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/187</b> </p> <p><b>(0%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/155 (0.65%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2/154 (1.30%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/24 (0.00%) AM.</b> </p> <p><b>0/25 (0.00%) PM.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/23 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1/194 (0.52%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6/197 (3.05%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2/195 (1.03%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0011" title="NCT01453023 . Inhaled fluticasone furoate/vilanterol safety and tolerability, PK and PD study. http://clinicaltrials.gov/show/NCT01453023 (accessed 17/6/15). OliverA , VanBurenS , AllenA , HamiltonM , TombsL , InamdarA , et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clinical Therapeutics2014;36(6):928‐39.e1. ">NCT01453023</a> </p> <p>Cross‐over trial. 11 weeks (for a single period)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/25 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/25 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a><sup>a</sup> </p> <p>Cross‐over trial. 28 days for each period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/51 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/51 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/51 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> <p>Cross‐over trial. 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/27 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/27 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/26 (0.00%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0/27 (0.00%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4/403 (0.99%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5/403 (1.24%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>The main paper reports that 1 of the 52 withdrew during the study owing to an SAE, which occurred 4 days after the last dose in the FF 100 treatment period. This participant was provisionally diagnosed with moderate (grade 2) Still’s disease. Six weeks later, the participant was hospitalised. A diagnosis of histiocytic necrotising lymphadenitis (Kikuchi’s disease) was made on the basis of histology of an excised lymph node. Tapered prednisolone treatment, initiated at 60 mg per day, has been successful </p> <p>FF: fluticasone furoate; FP: fluticasone propionate; SAE: serious adverse event; SAL: salmeterol; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Forced expiratory flow in one second (FEV1)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>measure</b> </p> <p><b>time point/</b> </p> <p><b>duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI </b> </p> <p><b>100/25 mcg</b> </p> <p><b>Mean (SE), N, of MD (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VI 25 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL250/50 mcg twice‐daily</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI, unless otherwise stated)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>Trough FEV<sub>1</sub> </p> <p>At 0 to 12 weeks</p> <p>Change in baseline trough FEV<sub>1</sub> from baseline to week 12 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.441 L (0.022)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.365 L (0.022)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.457 L (0.022)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>Trough FEV<sub>1</sub> </p> <p>At 0 to 12 weeks</p> <p>Mean change in trough FEV<sub>1</sub> (pre‐bronchodilator and pre‐dose) from baseline to </p> <p>week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.368 L (0.0304),</b> </p> <p><b>n = 200</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.332 L (0.0302),</b> </p> <p><b>n = 203</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.196 L (0.0310),</b> </p> <p><b>n = 193</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 L (‐0.05 to 0.12) 0.17 L (0.09 to 0.26) 0.14 L (0.05 to 0.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>Trough FEV<sub>1</sub> combining all treatment periods </p> <p>At 0 to 2 weeks</p> <p>3 of 7 treatments (2 weeks) separated by 12 to 14‐day washout periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.200 L,</b> </p> <p><b>n = 158</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.087 L,</b> </p> <p><b>n = 158</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>12 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted treatment difference 0.108 L (0.040 to 0.176)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> <p>Weighted mean FEV<sub>1</sub> over the day </p> <p>At day 14</p> <p>Weighted mean FEV<sub>1</sub>, over 0 to 24 hours post dose at day 14 </p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose: 3.188 L</b> <br/> <b>(3.112 to 3.265), n = 24</b> </p> <p><b>PM dose: 3.233 L</b> <br/> <b>(3.159 to 3.306), n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.811 L</b> <br/> <b>(2.729 to 2.893),</b> </p> <p><b>n = 20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 0.377 L (90% CI 0.293 to 0.462)</p> <p>PM vs placebo 0.422 L (90% CI 0.337 to 0.507)</p> <p>AM vs PM ‐0.44 L</p> <p>(90% CI ‐0.125 to 0.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) </p> <p>Day 14 pre‐treatment (trough) AM FEV<sub>1</sub> </p> <p>At day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose: 3.191 L</b> <br/> <b>(3.087 to 3.295), n = 24</b> </p> <p><b>PM dose: 3.285 L</b> <br/> <b>(3.187 to 3.383),</b> </p> <p><b>n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.788 L</b> <br/> <b>(2.684 to 2.892),</b> </p> <p><b>n = 22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 0.403 L (90% CI 0.272 to 0.533)</p> <p>PM vs placebo 0.496 L (90% CI 0.369 to 0.624)</p> <p>AM vs PM ‐0.094 L (90% CI ‐0.221 to 0.034)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a>) </p> <p>Day 14 pre‐treatment (trough) PM FEV<sub>1</sub> </p> <p>At day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose</b> : <b>3.153 L</b> <br/> <b>(3.049 to 3.258), n = 24</b> </p> <p><b>PM dose: 3.188 L</b> <br/> <b>(3.088 to 3.288), n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.879 L</b> <br/> <b>(2.775 to 2.982),</b> </p> <p><b>n = 23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 0.275 L (90% CI 0.169 to 0.380)</p> <p>PM vs placebo 0.309 L (90% CI 0.205 to 0.413)</p> <p>AM vs PM ‐0.034</p> <p>(90% CI ‐0.138 to 0.070)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>Change in baseline trough FEV<sub>1</sub> </p> <p>At 24 weeks</p> <p>Change from baseline in clinic visit trough (pre‐bronchodilator and pre‐dose) FEV<sub>1</sub> at end of 24‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.201 L (0.0303),</b> </p> <p><b>n = 186</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.394 L (0.0302),</b> </p> <p><b>n = 187</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.183 L (0.0300),</b> </p> <p><b>n = 190</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.19 L (‐0.28 to ‐0.11) 0.02 L (‐0.06 to 0.10) 0.21 L (0.13 to 0.29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) </p> <p>Change from baseline in weighted mean serial FEV<sub>1</sub> over 24 hours </p> <p>At 24 weeks</p> <p>Change from baseline in weighted mean serial FEV<sub>1</sub> over 0 to 24 hours post dose at week 24 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.328 L (0.0493),</b> </p> <p><b>n = 83</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.464 L (0.0470),</b> </p> <p><b>n = 89</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.258 L (0.0483),</b> </p> <p><b>n = 86</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14 L (‐0.27 to ‐0.00) 0.07 L (‐0.07 to 0.21) 0.21 L (0.07, 0.34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a> </p> <p>23 hours post challenge</p> <p>At day 29</p> <p>Cross‐over trial ‐ 28 days for each period</p> <p>Weighted mean change from baseline in FEV<sub>1</sub> between 0 and 2 hours following 22 to 23‐hour post‐treatment allergen challenge at day 29 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.227 L (0.0550),</b> </p> <p><b>n = 46</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.210 L (0.0549),</b> </p> <p><b>n = 49</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.372 L (0.0557),</b> </p> <p><b>n = 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF vs placebo 0.162 L (0.087 to 0.237)</p> <p>FF/VI vs placebo 0.145 L (0.069 to 0.222)</p> <p>FF/VI vs FF ‐0.017 L (‐0.091 to 0.057)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>) </p> <p>Decrease from baseline 23 hours post challenge</p> <p>At day 29</p> <p>Maximum % decrease from baseline FEV<sub>1</sub> between 0 and 2 hours following 22 to 23‐hour post‐treatment allergen challenge at day 29 of each treatment period (time frame: baseline and at day 29 of each treatment period (up to study day 197)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐13.206% (2.0491),</b> </p> <p><b>n = 46</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐14.040% (2.0435),</b> </p> <p><b>n = 49</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐24.991% (2.0736),</b> </p> <p><b>n = 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF vs placebo 10.951% (8.053 to 13.848)<br/> FF/VI vs placebo 11.785% </p> <p>(8.849 to 14.721)<br/> FF/VI vs FF 0.834% (‐2.010 to 3.678) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0012" title="NCT01128569 . Randomised study comparing the effects of inhaled fluticasone furoate (FF)/vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128569 (accessed 17/6/15). OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy2012;2(1):11. OliverA , QuinnD , GoldfradC , vanHeckeB , AyerJ , BoyceM . The effect of fluticasone furoate alone and in combination with vilanterol on the early asthmatic response 23 hours after dosing In patients with mild persistent asthma: results from a 28‐day randomised, controlled, cross‐over study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2758. ">Oliver 2012</a>) </p> <p>Change from baseline FEV<sub>1</sub> </p> <p>23 hours post challenge</p> <p>Minimum FEV<sub>1</sub> absolute change from baseline between 0 and 2 hours following 22 to 23‐hour post‐treatment allergen challenge at day 29 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.478 L (0.0767),</b> </p> <p><b>n = 46</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.479 L (0.0765),</b> </p> <p><b>n = 49</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.809 L (0.0775),</b> </p> <p><b>n = 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF vs placebo 0.330 L (0.232 to 0.429)<br/> FF/VI vs placebo 0.331 L (0.231 to 0.43)<br/> FF/VI vs FF 0.001 L (‐0.096 to 0.097) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a> </p> <p>Change from baseline 4 to 10 hours post challenge</p> <p>At day 21</p> <p>Cross‐over trial ‐ 21 days</p> <p>LAR: absolute change from baseline in minimum FEV<sub>1</sub> between 4 and 10 hours following 1‐hour post‐treatment allergen challenge at day 21 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.216 L</b> <br/> <b>(‐0.343 to ‐0.088),</b> </p> <p><b>n = 26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.188 L</b> <br/> <b>(‐0.315 to ‐0.061),</b> </p> <p><b>n = 27</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.536 L</b> <br/> <b>(‐0.676 to ‐0.396),</b> </p> <p><b>n = 22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.731 L</b> <br/> <b>(‐0.878 to ‐0.584),</b> </p> <p><b>n = 20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0013" title="NCT01128595 . Randomised study comparing the effects of inhaled FF/GW642444M combination, FF and GW642444M on an allergen induced asthmatic response. http://clinicaltrials.gov/show/NCT01128595 (accessed 17/6/15). OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:386s [P2161]. OliverA , BjermerL , QuinnD , SagguP , ThomasP , YarnallK , et al. Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy2013;68(9):1136–42. OliverA , QuinnD , SagguP , ThomasP , YarnallK , LootvallJ , et al. Fluticasone furoate and vilanterol suppress allergen‐induced bronchial hyper‐responsiveness to methacholine [Abstract]. Allergy2012;67:452. ">Oliver 2013</a>) </p> <p>Change from baseline 4 to 10 hours post challenge</p> <p>At day 21</p> <p>LAR: absolute change from baseline in weighted mean FEV<sub>1</sub> between 4 and 10 hours following 1‐hour post‐treatment allergen challenge at day 21 of each treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.018 L</b> <br/> <b>(‐0.089 to 0.125), n = 26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.018 L</b> <br/> <b>(‐0.089 to 0.124),</b> </p> <p><b>n = 27</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.298 L</b> <br/> <b>(‐0.415 to ‐0.181),</b> </p> <p><b>n = 22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.466 L</b> <br/> <b>(‐0.589 to ‐0.343),</b> </p> <p><b>n = 20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>Change from baseline trough FEV<sub>1</sub> </p> <p>At day 168</p> <p>24 weeks' duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.281 L (0.0191),</b> </p> <p><b>n = 397</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.300 L (0.0193),</b> </p> <p><b>n = 389</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.019 L (‐0.073 to 0.034)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AM: morning; CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in one second; FF: fluticasone furoate; FP: fluticasone propionate; h: hour; LAR: late asthmatic response; MD: mean difference; PM: afternoon; SAL: salmeterol; SE: standard error; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Forced expiratory flow in one second (FEV1)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Peak expiratory flow</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure of PEF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 100/25 mcg</b> </p> <p><b>Mean (SD, unless otherwise stated), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SD, unless otherwise stated), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE ), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> <p><b>Mean (SE), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Mean (SE, unless otherwise stated), N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI, unless otherwise stated)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, AM</p> <p>Change from baseline in AM PEF Averaged over 12‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44.3 L/min (2.25)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19.1 L/min (2.25)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47.7 L/min (2.25)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.20 L/min (18.96 to 31.44), 100/25 vs 100 FF</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, PM</p> <p>Change from baseline in AM PEF Averaged over 12‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39.7 L/min (2.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15.5 L/min (2.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41.7 L/min (2.24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.20 L/min (17.99 to 30.41), 100/25 vs 100 FF</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, PM</p> <p>Mean change from baseline in daily PM PEF averaged over 12‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26.4 L/min</b> </p> <p><b>(SE 2.35), n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14.1 L/min</b> </p> <p><b>(SE 2.34), n = 204</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐1.8 L/min (2.36),</b> </p> <p><b>n = 202</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.30 L/min (5.80 to 18.80), 28.20 L/min (21.67 to 34.73), 15.90 L/min (9.39 to 22.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, AM</p> <p>Only 1 (FF/VI) condition reported. Trial reported as conference abstract with limited information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline to day 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Least squares mean change calculated from baseline to day 15</p> <p>Least squares mean change in last 7 days, mean PEF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24.1 (2.46) AM</b> </p> <p><b>21.4 (2.58) PM</b> </p> <p><b>n = 172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐2.9 (2.44) AM</b> </p> <p><b>‐5.2 (2.51) PM</b> </p> <p><b>n = 187</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks' duration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39.1 L/min (3.01), n = 155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10.5 L/min (3.03), n = 154</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjusted treatment difference 28.5 L/min (20.1 to 36.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010758-bbs2-0007" title="KempsfordR , OliverA , TombsL , BalJ . The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2090]. KempsfordRD , OliverA , BalJ , TombsL , QuinnD . The efficacy of once‐daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine2013;107(12):1873‐80. NCT01287065 . A randomised, repeat‐dose, placebo‐controlled, double‐blind study to evaluate and compare the efficacy of fluticasone furoate/vilanterol inhalation powder, when administered either in the morning or in the evening, in male and female asthmatic subjects, 2010. http://clinicaltrials.gov/show/NCT01287065(accessed 9/8/16). ">Kempsford 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐treatment</p> <p>Pre‐treatment PEF at days 1 to 12</p> <p>Cross‐over trial. Each period lasted 14 days with a 14 to 21‐day washout period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose:</b> </p> <p><b>510.4 L/min</b> <br/> <b>(95% CI 492.9 to 527.8), n = 24</b> </p> <p><b>PM dose:</b> </p> <p><b>535.3 L/min</b> <br/> <b>(95%CI 518.1 to 552.5), n = 25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>466.3 L/min</b> <br/> <b>(95% CI 448.8 to 483.9), n = 24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 44.0 L/min (90% CI 31.2 to 56.9)</p> <p>PM vs placebo 69.0 L/min (90% CI 55.9 to 82.1)</p> <p>AM vs PM ‐25.0 L/min (90% CI ‐37.9 to ‐12.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐treatment</p> <p>Pre‐treatment PEF (PM) at days 1 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AM dose:</b> </p> <p><b>517.6 L/min</b> <br/> <b>(95% CI 503.0 to 532.2), n = 24</b> </p> <p><b>PM dose:</b> </p> <p><b>521.4 L/min</b> <br/> <b>(95% CI 507.1 to 535.7), n = 26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>453.2 L/min</b> <br/> <b>(95% CI 438.5 to 467.9), n = 24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM vs placebo 64.4 L/min (90% CI 52.9 to 76.0)</p> <p>PM vs placebo 68.2 L/min (90% CI 56.5 to 79.8)</p> <p>AM vs PM ‐3.7 L/min (90% CI ‐15.2 to 7.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, AM</p> <p>4 weeks</p> <p>Mean change from baseline in daily trough (AM) PEF averaged over 24‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18.2 L/min (2.97),</b> </p> <p><b>n = 193</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>51.8L/min (2.94), n = 197</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18.8L/min (2.95), n = 195</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐33.60 L/min (‐41.79 to, ‐25.41), ‐0.60 L/min (‐8.80 to 7.60), 33.00 L/min (24.84 to 41.16) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline, PM</p> <p>Mean change from baseline in daily trough (PM) PEF averaged over 24‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9.1 L/min (2.98),</b> </p> <p><b>n = 192</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39.8 L/min (2.93), n = 197</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13.6 L/min (2.96), n = 194</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐30.70 L/min (‐38.89 to ‐22.51), ‐4.50 L/min (‐12.73 to 3.73), 26.20 L/min (18.04 to 34.36) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AM: morning; CI: confidence interval; FF: fluticasone furoate; PEF: peak expiratory flow; PM: evening; SD: standard deviation; SE: standard error; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Peak expiratory flow</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010758-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Asthma symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 100/25 mcg </b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 100 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF 200 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FF/VI 200/25 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP/SAL250/50 mcg twice‐daily</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FP 500 mcg</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Mean (SE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0002" title="BatemanED , O'ByrnePM , BusseWW , LotvallJ , BleeckerER , AndersenL , et al. Once‐daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax2014;69(4):312‐9. NCT01086384 . Asthma Exacerbation Study. http://clinicaltrials.gov/ct2/show/results/NCT01086384 (accessed 17/6/15). ">Bateman 2014</a> </p> <p>≥ 24 to 78 weeks' duration</p> <p>Responder analysis results: ORs for FF/VI vs FF at week 12 (1.49, 95% CI 1.20 to 1.84), week 36 (1.49, 95% CI 1.21 to 1.83) and at endpoint (1.50, 95% CI 1.23 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACQ7 mean difference and responder analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0003" title="BernsteinDI , BatemanED , WoodcockA , TolerWT , ForthR , JacquesL , et al. Efficacy and safety of once‐daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A6671. [CENTRAL: 1035521; CRS: 4900126000023032] EUCTR2012‐002797‐32‐DE . Efficacy/safety study of fluticasone furoate/vilanterol combination and fluticasone furoate in adult and adolescent asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐002797‐32‐DE (accessed 18/6/15). NCT01686633 . A randomized, double‐blind, parallel group, multicenter study of fluticasone furoate/vilanterol 200/25 mcg inhalation powder, fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents. http://clinicaltrials.gov/show/NCT01686633 (accessed 18/6/15). ">Bernstein 2014</a> </p> <p>Change from baseline in percentage of symptom‐free 24‐hour periods during 12‐week treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline % symptom‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27.2 (1.74)</b> </p> <p><b>n = 345</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19.4 (1.74)</b> </p> <p><b>n = 346</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29.0 (1.74)</b> </p> <p><b>n = 346</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0004" title="HZA106827: A randomised, double‐blind, placebo‐controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. http://www.gsk‐clinicalstudyregister.com/study/106827#ps (accessed 17/6/15). Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics. http://clinicaltrials.gov/show/NCT01165138 (accessed 17/6/15). BleeckerER , LotvallJ , O'BrynePM , WoodcockA , BusseWW , ForthR , et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:370s [P2091]. BleeckerER , LotvallJ , O'ByrnePM , WoodcockA , BusseWW , KerwinEM , et al. Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. Journal of Allergy and Clinical Immunology: In Practice2014;2(5):553‐61. [CENTRAL: 1017358; CRS: 4900126000021864; EMBASE: 2014708281; PUBMED: 25213048] SvedsaterH , JacquesL , GoldfradC , BleeckerER , O'ByrnePM , WoodcockA . Ease of use of a two‐strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. European Respiratory Journal2013;42(Suppl 57):128‐9. [CRS: 4900132000000863; EMBASE: 71842452] ">Bleecker 2012</a> </p> <p>Change from baseline in % of symptom‐free 24‐hour periods during 12‐week treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline % symptom‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32.5 (2.14),</b> </p> <p><b>n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20.4 (2.13),</b> </p> <p><b>n = 204</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14.6 (2.15), n = 202</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12.10 (6.18 to 18.02), 17.90 (11.95 to 23.85), 5.80 (‐0.13 to 11.73)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0006" title="HojoM , IikuraM , HirashimaJ , SuzukiM , IzumiS , SugiyamaH . A comparison of anti‐inflammatory effect of once‐daily fluticasone furoate/vilanterol 200/25 with twice‐daily fluticasone propionate/salmeterol 500/50 in severe asthmatics. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A4280. [CENTRAL: 1101091; CRS: 4900132000009922; EMBASE: 72052155] ">Hojo 2015</a> </p> <p>Trial reported as conference abstract with limited information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0008" title="Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). https://clinicaltrials.gov/ct2/show/NCT01573624accessed Dec 2015. LeeLA , YangS , KerwinE , TrivediR , EdwardsLD , PascoeS . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose‐ranging study. Respiratory Medicine2014;109(1):54‐62. [CENTRAL: 1020064; CRS: 4900126000022534; EMBASE: 2014869631; PUBMED: 25452139] ">Lee 2014</a> </p> <p>LS mean change in symptom‐free days during 2‐week treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LS mean change in symptom‐free days (SE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7.3 (1.67) n = 172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.8 (1.64) n = 187</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0009" title="JiangtaoL , CrawfordJ , JacquesL , StoneS . Efficacy and safety of once‐daily fluticasone furoate/vilanterol 200/25 mcg compared with twice‐daily fluticasone propionate 500 mcg in asthma patients of Asian ancestry [Abstract]. Respirology (Carlton, Vic.)2013;18(Suppl 4):111 [PS107]. LinJ , KangJ , LeeSH , WangC , ZhouX , CrawfordJ , et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respiratory Medicine2015;109(1):44‐53. [CENTRAL: 1042748; CRS: 4900126000023443; EMBASE: 2014615181; PUBMED: 25524507] NCT01498653 . Evaluating the efficacy and safety of fluticasone furoate/vilanterol trifenatate in the treatment of asthma in adolescent and adult subjects of Asian ancestry. http://clinicaltrials.gov/show/NCT01498653 (accessed 17/6/15). ">Lin 2013</a> </p> <p>% of symptom‐free 24‐hour periods, weeks 1 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% symptom‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25.4 (2.74),</b> </p> <p><b>n = 155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20.6 (2.77),</b> </p> <p><b>n = 152</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.9 (‐2.8 to 12.5)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a> </p> <p>Change from baseline in ACT scores at week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.9 (0.29), n = 164</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.8 (0.27), n = 183</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.9 (0.28), n = 169</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.90 (‐1.68 to ‐0.12), 0.00 (‐0.79 to 0.79), 0.90 (0.14 to 1.66)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010758-bbs2-0010" title="NCT01134042 . Study HZA106829: Efficacy/safety study of fluticasone furoate/vilanterol (GW642444) in adult and adolescent asthmatics, 2010. http://clinicaltrials.gov/show/NCT01134042(accessed 9/8/16). O'ByrnePM , BleeckerER , BatemanED , BusseWW , WoodcockA , ForthR , et al. Once‐daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal2014;43(3):773‐82. ">NCT01134042</a>) </p> <p>Change from baseline in ACT scores at week 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.2 (0.30), n = 147</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.5 (0.28), n = 170</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.7 (0.29), n = 162</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.30 (‐1.10 to 0.50), 0.50 (‐0.32 to 1.32), 0.80 (0.01 to 1.59)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010758-bbs2-0014" title="NCT01147848 . HZA113091 Efficacy and safety of fluticasone furoate/vilanterol (GW642444) in adults and adolescents. http://clinicaltrials.gov/show/NCT01147848 (accessed 18/6/15). WoodcockA , BleeckerER , LotvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma [Abstract]. European Respiratory Society 22nd Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:313s [P1795]. WoodcockA , BleeckerER , LötvallJ , O'ByrnePM , BatemanED , MedleyH , et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest2013;144(4):1222‐9. ">Woodcock 2013</a> </p> <p>Change from baseline in ACT scores at day 168 and at</p> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change from baseline ACT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.3 (0.16), n = 354</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.0 (0.16),</b> </p> <p><b>n = 348</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.2 (‐0.2 to 0.7)</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>ACT: asthma control test; CI: confidence interval; FF: fluticasone furoate; FP: fluticasone propionate; LS: least squares; MD: mean difference; NR: not reported; OR: odds ratio; SAL: salmeterol; SE: standard error; VI: vilanterol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Asthma symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/full#CD010758-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">FF/VI 100/25 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in quality of life (measured by AQLQ at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.3 [0.14, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FEV<sub>1</sub> Litres <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.09, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PEFR AM L/min (change from baseline at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.3 [26.59, 40.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PEFR PM L/min (change from baseline at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.2 [21.67, 34.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in asthma symptoms (measured by ACT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.9 [1.22, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">FF/VI 100/25 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">FF/VI 100/25 versus same dose of FF</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in quality of life (measured by AQLQ at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.00, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.86, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.42, 6.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Trough FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PEFR AM (change from baseline at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.29 [15.72, 24.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PEFR PM (change from baseline at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.52 [14.03, 23.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in asthma symptoms (measured by ACT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [‐0.04, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">FF/VI 100/25 versus same dose of FF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">FF/VI 100/25 versus same dose VI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">FF/VI 100/25 versus same dose VI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">FF/VI 100/25 versus FP 500 µg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.10, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">FF/VI 100/25 versus FP 500 µg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">FF/VI 100/25 versus FPS 250/50 bd</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in quality of life (measured by AQLQ at 24 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.03, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.21, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.07, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in asthma symptoms (measured by ACT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.20, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">FF/VI 100/25 versus FPS 250/50 bd</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">FF/VI 100/25 µg versus FF/VI 200/25 µg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.50, 8.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">FF/VI 100/25 µg versus FF/VI 200/25 µg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">FF/VI 200/25 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 FEV<sub>1</sub> Litres <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.13, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in asthma symptoms (measured by ACT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.9 [0.12, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">FF/VI 200/25 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">FF/VI 200/25 µg versus FP 500 µg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in quality of life (measured by AQLQ at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.08, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in quality of life (measured by AQLQ at 24 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.15, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 OLD***Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.08, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.22, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.25, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PEFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.6 [20.23, 36.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 PEFR AM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.0 [24.84, 41.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 PEFR PM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.2 [18.04, 34.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 % symptom‐free days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.8 [‐2.84, 12.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change in asthma symptoms (measured by ACT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.01, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">FF/VI 200/25 µg versus FP 500 µg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010758-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">FF/VI 200/25 versus same dose of FF</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in quality of life (measured by AQLQ at 12 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.08, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in quality of life (measured by AQLQ at 24 wk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.14, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.06 [0.72, 50.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FEV<sub>1</sub> Litres <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.10, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PEFR AM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.6 [25.41, 41.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PEFR PM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.7 [22.51, 38.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in asthma symptoms (measured by ACT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.3 [‐0.50, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">FF/VI 200/25 versus same dose of FF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010758.pub2/references#CD010758-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010758.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010758-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010758-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010758-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010758-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010758-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD010758-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010758-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010758\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010758\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010758\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010758\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010758\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010758.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010758.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010758.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010758.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010758.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728244313"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010758.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728244317"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010758.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebfbedd59f46e',t:'MTc0MDcyODI0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 